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ABSTRACT 
 
 
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the human central 
nervous system (CNS). Although demyelination represents the major histopathological 
hallmark of the disease, currently the mechanism that mediates myelin loss is not fully 
understood. My PhD study aimed to understand how myelin is damaged in experimental 
autoimmune encephalomyelitis (EAE), the most commonly used animal model of MS, by 
combining two photon in vivo imaging with confocal microscopy and ultrastructural analysis.  
 
For my experiments I used the chronic EAE model that is induced in BiozziABH mice by 
immunization with myelin oligodendrocytes glycoprotein (MOG). The clinical course of in 
this model resembles the human disease multiple sclerosis as mice initially develop a chronic 
relapsing-remitting form of EAE, which later evolves into a steady progression of the disease. 
In this model, I investigated the process of demyelination and the sequence that leads to 
myelin damage. My findings suggest that oligodendrocyte (OL) damage in EAE follows an 
outside-to-inside pattern, affecting myelin first and only later leading to OLs loss.  
Once I identified myelin as the primary target of the immune attack, I used time-lapse in vivo 
imaging to observe how myelin damage is initiated in acute EAE lesions. To efficiently label 
this subcellular compartment in vivo, I established a novel strategy based on the application 
of a specific vital dye (MitoTracker Red) which, at a given concentration, stains the myelin 
sheath, to the exposed spinal cord. In vivo imaging of fluorescently labelled axons and their 
myelin sheath revealed that in active demyelinating lesions, myelin is detached from axons in 
bulb-like structures that we called “myelinosomes”. Such myelinosomes are detectable in 
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acute and in chronic stages of the MS model, with the highest frequency being present at the 
peak of inflammatory activity.  
I then correlated light and electron microscopy as described previously (Bishop et al., 2011) 
to visualize the ultrastructure of myelinosomes and their cellular context. This technique 
confirmed the presence of myelinosomes in acute lesions and showed that in some cases they 
encompass the entire myelin sheath, while in others they consist of single or few myelin 
leaflets.  
From the ultrastructural analysis, I also gained some information regarding the formation of 
these myelin outfoldings. I noticed that myelinosomes are usually in direct contact with 
phagocytic cells, which completely engulf them. Thus, I hypothesized that these cells drive 
the formation of myelin bulbs and the subsequent demyelination.  I therefore investigated the 
mechanisms that mediate the development of myelinosomes. I could show that the transfer of 
anti-MOG antibodies not only enhanced demyelination, but also increased the frequency of 
myelinosomes suggesting that antibodies mediate the adhesive interaction between myelin 
and phagocyte. 
 
In the last part of my project, I studied the relevance of my findings for MS. Here, I could 
confirm key findings of my in vivo analysis in human brain biopsies from MS patients. For 
example, I observed a similar outside-inside pattern of oligodendrocyte damage in 
activeldemyelinating MS lesions where extensive demyelination was present in the absence 
of OLs cell loss. Moreover, I could detect myelinosomes-like structures in MS biopsies, 
which further supports the idea that in demyelinating pathologies the formation of 
myelinosomes might underlie myelin removal.   
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ZUSAMMENFASSUNG  
 
Die Multiple Sklerose (MS) ist eine immunvermittelte demyelinisierende Erkrankung des 
zentralen Nervensystems (ZNS). Obwohl die Demyelinisierung das zentrale 
histopathologische Korrelat dieser Erkrankung ist, ist der Mechanismus, der zum 
Myelinverlust führt, nicht gut verstanden. In meiner Doktorarbeit habe ich deswegen 
untersucht, wie Myelin in dem am häufigsten verwendeten Tiermodell der MS, der 
experimentellen autoimmunen Enzephalomyelitis (EAE), geschädigt wird. Für diese 
Untersuchungen habe ich 2-Photon in vivo Mikroskopie mit konfokaler Mikroskopie und 
ultrastrukturellen Analyse kombiniert.  
Für die Experimente wurde ein chronisches EAE Modell, das in BiozziABH Mäusen durch 
die Immunisierung mit Myelin Oligodendrozyten Glykoprotein (MOG) induziert wird, 
verwendet. Dieses Modell zeigt einen der menschlichen Erkrankung ähnlichen 
Krankheitsverlauf mit einer  frühen schubförmig-remittierenden Phase, auf welche ein 
chronisch-progredienter Krankheitsprozess folgt. In diesem Modell untersuchte ich zunächst, 
in welchen zellulären Kompartment die Oligodendrozytenschädigung initiert wird. Meine 
Ergebnisse zeigen, dass Oligodendrozyten in der EAE von außen nach innen geschädigt 
werden. Zuerst ist Myelin betroffen und erst in einem späteren Stadium kommt es zu einem 
Oligodendrozytenverlust.  
Nachdem diese Untersuchungen das Myelin als das Primärziel des entzündlichen Angriffs 
identifiziert hatten, studierte ich mit Hilfe der time lapse in vivo Mikroskopie, wie die 
Myelinschädigung in akuten entzündlichen Läsionen induziert wird. Zu diesem Zweck  habe 
ich zunächst eine neuartige Strategie etabliert, um effizient Myelin in vivo zu färben. Diese 
Strategie basiert auf der Applikation eines spezifischen Vitalfarbstoffes (MitoTracker Red) 
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auf das Rückenmark, welcher in einem bestimmten Konzentrationsbereich spezifisch die 
Myelinhülle färbt. Die In vivo Mikroskopie von fluoreszenz-markierten Axone und ihrer 
Myelinschicht zeigte dann, dass sich in aktiv demyelinisierenden Läsionen das Myelin von 
den Axonen in „ballartigen“ Strukturen ablöst, die wir „Myelinosomen“ benannt haben. 
Solche Myelinosomen finden sich in akuten und chronischen Stadien der EAE, wobei die 
höchste Dichte , während der Zeit der maximalen Entzündungsaktivität beobachtet wird. 
Um mehr über die Ultrastruktur und den zellulären Kontext der Myelinosomen zu erfahren, 
haben wir einen korrelativen Licht- und Elektronenmikroskopie-Ansatz verwendet, der 
bereits in Bishop et al. (2011) beschrieben wurde. Diese Methode bestätigt die Anwesenheit 
von Myelinosomen in akuten EAE Läsionen und zeigt, dass diese in einigen Fällen die 
gesamte Myelinhülle umfassen, während in anderen diese nur aus einzelnen oder wenigen 
Myelinschichten bestehen.  
Die ultrastrukturelle Analyse lieferte auch wichtige Hinweise zur Pathogenese der  
Myelinosomenbildung. So konnten wir zeigen, dass Myelinosomen häufig von Phagozyten 
kontaktiert werden, welche vollständig die Myelinosomen umhüllen und einschließen. Daher 
folgerte ich, dass diese Zellen verantwortlich für die Bildung der Myelinosomen und die 
nachfolgende Demyelinisierung sind. Als nächstes untersuchte ich den Mechanismus der 
Myelinosombildung genauer.  Ich konnte zeigen, dass der Transfer von anti-MOG 
Antikörpern nicht nur die Demyelinisierung verstärkt, sondern auch die Häufigkeit der 
Myelinosomen erhöht. Dies legt nahe, dass myelin-reaktive Antikörper die Adhäsion 
zwischen Myelinsom und Phagozyten vermitteln. 
Im letzten Teil meines Projekts untersuchte ich dann die Bedeutung meiner Ergebnisse für 
MS. Interessanterweise konnte ich zeigen, dass wichtige im Tiermodell erhobene Befunde 
auch auf die menschliche Erkrankung übertragen werden können. So fand ich bei der  
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Untersuchung von Hirnbiopsien, dass auch in aktiven MS Läsionen die 
Oligodendrozytenschädigung mit dem Verlust von Myelin beginnt. Darüberhinaus konnte ich 
auch Myelinosom-ähnliche Strukturen in MS Biopsien entdecken. Diese Beobachtungen 
unterstützen die Hypothese, dass Myelin in demyelinisierenden Pathologien über die Bildung 
von Myelinosomen entfernt wird.  
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CHAPTER I – Introduction 
 
1. Multiple Sclerosis 
 
Introduction and history of the disease 
 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), in 
which a complex activation of the immune system leads to myelin damage and axonal 
pathology.  
One of the first recognised medical reports was published in 1840 by McKenzie who 
described a 23 years-old man with progressive “palsy of his limbs and confusion of vision”, 
also displaying incontinence and asymmetric arms weakness. These symptoms disappeared 
after two months and his motor function and eyesight were restored
 
(McKenzie, 1840). Few 
years earlier, two independent reports by Sir Robert Carswell and Jean Cruveilhier, described 
and illustrated MS-like clinical manifestations and CNS lesions; however, neither of them 
categorized such disease as a newly discovered pathology. Carswell’s atlas was published in 
1837 and the legends to his illustrations describe “a peculiar diseased state of the cord and 
pons to the grey substance” and “patches on the spinal cord occupying the medullary 
substance which was hard, semitransparent and atrophie” (Pearce, 2005). Similar to his 
colleague, Cruveilhier reported CNS lesions as “reddish grey islets” and referred to their 
appearance as “a grey degeneration of the columns of the spinal cord (…)” and  “grey 
degeneration in the cord, brainstem and cerebellum” (Flamm, 1973).  
Although a lot of pathologists and physicians were interested in diseases of the brain, Jean-
Martin Charcot was the first who successfully described the clinical and pathological 
hallmarks of MS, which was known as “Charcot disease” until 1921. He caught interest in the 
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disease after observing the early symptoms and the progressive disability of his housemaid, 
whose autopsy showed scattered plaques in her brain and spinal cord. In 1866, Charcot and 
his colleague Vulpian referred to this disease as “Sclerose en plaques disseminee”, and a 
couple of years later he gave a very accurate description of the main neurological and 
pathological findings: clinically, the disorder is characterized by different symptoms, among 
which tremor, nystagmus and scanning speech; pathologically, he showed that loss of myelin, 
thickening of blood vessels, fatty macrophages, gliosis scar, and damaged axons were evident 
in the CNS of the patients (Clanet, 2008).  
Nowadays we are aware of many historical figures who lived before Charcot and that 
suffered a MS-like disease. Among those is Sir Augustus D’Este, grandson of King George 
III. He kept a diary where he carefully documented the progression of his disorder, from 
weakness, numbness, difficulty in walking, spasms, to depression. His diary with its 
meticulous notes is widely accepted as possibly the first known patient’s description of MS 
(Pearce, 2005; Firth, 1948). 
 
Clinical course and diagnosis of MS 
 
MS is a heterogeneous disease that can manifest through at least four different clinical 
subtypes (Lublin et al., 2014): i) relapsing-remitting MS (RRMS), characterized by an 
alternation of periods, in which the patient shows neurologic symptoms followed by full or 
partial recovery, this type occurs in 80-85% of cases; ii) primary progressive MS (PPMS), in 
which no recovery periods can be observed (10-15% of cases); iii) secondary progressive MS 
(SPMS), developed by most of the RRMS patients and characterized by a steady progression 
of the symptoms; iiii) progressive relapsing (PRMS), characterized by a continuous 
progression of the disease from the onset with defined attacks, with or without recovery. This 
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description of MS subtypes was presented in 1996 by the US National Multiple Sclerosis 
Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis, when the 
Committee also provided a definition of benign MS, in which the patient does not show 
neurological deficits 15 years after the onset of the disease, and malignant MS, which is 
characterized by a rapid course of the disease with strong disability and eventually death 
(Lublin et al., 2014; Milo and Miller, 2014)
 
(Figure 1). 
In 2012 the same Committee gathered to review the old clinical course descriptions, and two 
new clinical courses were added to the pre-existing list: i) clinically isolated syndrome (CIS), 
described as the first clinical presentation of the disease (suggesting that it may be MS), and 
ii) radiologically isolated syndrome (RIS), where the patient fails to show any clinical signs 
although MS-like plaques can be identified by MRI imaging (Lublin et al., 2014).  
As MS lesions are typically disseminated both in time and space, diagnosis is mainly based 
on clinical symptom manifestations, which can be referred to white matter lesions. Among 
those clinical symptoms, the most common are numbness, motor weakness, visual deficit, 
diplopia, gait disturbances, but also incontinence, sensory loss, ataxia, as well as depression 
and cognitive dysfunction. Besides clinical observations, specific tests can help to diagnose 
MS: cerebrospinal fluid (CSF) analysis, electrophysiological studies, and MRI. The majority 
of MS patients present oligoclonal IgG bands in their CSF; the presence of 2 or more bands 
indicates CNS-specific antibody production and it is a fundamental step in defining the 
pathological scenario as MS. Electrophysiological studies can be used to assess whether there 
are demyelinating lesions, as those normally lead to delayed latencies of visual, 
somatosensory and auditory evoked potentials. Finally, MRI has become the most sensitive 
technique to reveal MS lesions, and a crucial tool to monitor disease progression, measure 
brain atrophy and axonal loss, estimate lesion density, both in grey and white matter (Milo 
and Miller, 2014; Compston and Coles, 2008).   
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Figure 1 - Multiple sclerosis clinical subtypes: Progressive Relapsing MS (PRMS), Primary 
Progressive MS (PPMS), Secondary Progressive MS (SPMS), Relapsing Remitting MS (RRMS). 
Inspire by Coles, 2009. 
 
Epidemiology 
 
MS affects primarily young adults, with the first symptoms usually appearing in the late 
20s/early 30s; the incidence of the disease decreases with age, and it becomes rare in people 
in their 50s or above. The risk is higher among white non-Hispanic individuals, and it appears 
to be lower in black, Hispanic and Asian populations (Ascherio et al., 2012).  
The susceptibility to MS is influenced by different determinants, including genetic 
components as well as environmental factors. Studies on twins and siblings have shown that 
the strongest genetic risk is associated with the HLA-DRB1 gene on chromosome 6p21, 
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specifically the HLA-DRB1*1501 allele. HLA (Human Leukocyte Antigen) molecules are 
involved in immune responses and antigen binding and presentation. This might explain why 
the DRB1 gene is associated with higher susceptibility to MS; however, the exact 
mechanisms are still unknown (Hauser et al., 2006).  
As mentioned above, the environment also plays an important role in the development of MS: 
viral and bacterial infections, dietary habits, pollution, exposure to minerals or animals, and 
many other factors have been investigated. A prominent candidate is infection with the 
Epstein Barr virus (EBV), a double-stranded DNA virus, which is transmitted mainly by 
saliva. Its infection is asymptomatic in the first years of life, but it can lead to acute fever 
(known as infectious mononucleosis) when it affects adults. The risk of developing MS 
appears to be lower in EBV-negative individuals, while individuals infected with virus are 
more susceptible to the disease.  
Additional studies have revealed high vitamin D levels as a possible protective factor in MS, 
and have shown how cigarette smoking increases the risk of developing MS. Therefore, 
vitamin D supplementation and smoking cessation are likely to decrease the risk of MS and 
improve life of individuals with MS (Ascherio et al., 2012; Schmidt et al., 2007). 
 
Pathology of MS 
 
MS is characterized by demyelinating plaques scattered throughout the CNS, mostly in white 
matter areas but also found in gray matter. Hallmarks of the lesions are the presence of 
inflammatory cells, damaged axons, myelin debris, and gliosis. According to a study 
published in 2000 by Lucchinetti et al., we can identify 4 types of active demyelinating 
lesions depending on their demyelination pattern: I) Pattern I, “macrophage-associated 
demyelination”, characterized by T cells infiltration and macrophages activation, the latter 
seemingly responsible for the myelin damage; II) Pattern II, “antibody-mediated 
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demyelination”, in which immune infiltrates are composed of T cells and macrophages as in 
pattern I, and demyelination seems induced by antibodies and activated complement; III) 
Pattern III, “distal oligodendrogliopathy and apoptosis”, in which inflammation is less 
prominent and again driven by T cells and macrophages, but it is mainly characterized by 
distal degeneration of oligodendrocytes processes and diffuse apoptosis;   IV) Pattern IV, 
“primary oligodendroglia degeneration”, this is the least common pattern of demyelination in 
MS and oligodendrocytes degeneration is the most prominent feature (Lucchinetti et al., 
2000; Lassman et al., 2001). The lesion patterns described above are all characterized by the 
infiltration of T cells and macrophages. In fact, although the CNS is considered an immune-
privileged site as the blood brain barrier (BBB) protects the brain from the entry of blood-
borne molecules and circulating leukocytes, in MS disruption of the BBB is an early event 
that allows leukocytes to enter the CNS parenchyma (Prat et al., 2002). For a long time MS 
was believed to be mediated only by autoreactive myelin-specific CD4+ T cells, but it has 
become more and more clear that instead it involves different immune cell types from both 
adaptive and innate immune system, as well as glial cells (Duffy et al., 2014). Below I will 
briefly review the different cellular subsets involved in the pathogenesis of MS and discuss 
their contribution to the disease (Figure 2). 
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Figure 2 - schematic representation of the contribution of different immune and glial cells to the 
pathogenesis of MS. 
 
T lymphocytes  
 
Thymus-derived T cells are part of the adaptive immune system and can be classified into 3 
main categories: T helper (Th/CD4+), cytotoxic (CD8+), and regulatory T (T reg) cells.  
T helper type 1 (Th1) cells differentiate in response to IL-12 and, once activated, release 
proinflammatory cytokines such as interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-
α) (Dittel et al., 2008). TNF-α has been found in MS lesions and elevated TNF-α levels in 
serum and CSF of MS patients correlated in some cases with disease progression. Therefore, 
it was proposed as a possible target in the therapy of the disease and a TNF-α receptor-
immunoglobulin G (IgG) 1 fusion protein called Lenercept was tested: while it appeared to 
have positive results in the animal model of MS, its administration in human didn’t show any 
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improvement (The Lenercept Multiple Sclerosis Study Group and The University of British 
Columbia MS/MRI Analysis Group, 1999). IFN-γ has also been investigated: one of the first 
studies that described the use of an antibody to IFN-γ, reported how the blockade of this 
cytokine can ameliorate the disease course in MS patients (Skurkovich et al., 2001).  
Conversely, a different subtype of T helper named T helper type 2 (Th2) cells are known to 
play a beneficial role, and release cytokines such as IL-4, IL-5, IL-10 and IL-13 (Bitain et al., 
2010).  
Another subtype of T helper lymphocytes are type 17 (Th17) cells, which differentiate in 
response to IL-23. These cells are described as pro-inflammatory cells and their signature 
cytokine is IL-17; recent studies have described that IL-17 receptor is expressed on human 
endothelial cells that form the brain blood barrier (BBB) (Kebir et al., 2007), and therefore it 
may be crucial in inducing a breach in the barrier with consequently trafficking of 
autoreactive T cells from the systemic compartment into the CNS parenchyma.  
Cytotoxic CD8+ T cells can also be subdivided in pro-inflammatory and anti-inflammatory, 
depending on the cytokines they produce: Tc1 and Tc17 belong to the pro-inflammatory 
family, releasing respectively IFN-γ and IL-17; Tc2 have an anti-inflammatory role and 
produce IL-4, IL-5, IL-10. Cytotoxic T cells have been reported in actively demyelinating 
lesions in MS, in close proximity to demyelinated axons, and with a higher density than 
CD4+; these findings suggest a role in the induction of tissue damage (Babbe et al., 2000; 
Skulina et al., 2004).  
The last category of T cells are the regulatory T cells (Treg). These cells act as 
immunomodulators of the adaptive immune system and are characterized by the expression 
of CD4, CD25, CD39 and the transcription factor FoxP3. Whether those cells play a big role 
in the modulation of disease initiation and progression, is not yet clear. However, a number of 
studies showed that Treg cells can be found in MS lesions as well as in CSF of MS patients, 
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and their density appears to be less frequent in the lesions compared to the CSF compartment, 
where they express an apoptotic phenotype (Fritzsching et al., 2011). Interestingly, it was 
also shown that CD39+ Treg cells can cope with a Th17 expansion during the remitting phase 
of MS, but not during relapse (Peelen et al., 2011).  
 
B lymphocytes 
 
B cells lymphocytes are part of the adaptive immune system and appear both as positive and 
negative modulators of immunity: in fact, not only are they responsible for the production of 
antibodies, but they also act as antigen presenting cells (APCs) and release soluble factors 
(Pistoia, 1997). Antibodies have already been described in the past as contributors to lesion 
formation, with IgG found in demyelinating lesions and on myelin sheaths (Lucchinetti et al., 
1996; Barnett et al., 2009). A more recent study confirmed IgG and IgM presence in both 
acute and chronic active and inactive lesions, independently of disease duration and clinical 
course (Sadaba et al., 2012), and it has been suggested that B cells are able to secrete 
additional factors toxic to the oligodendrocytes, thus contributing through different 
mechanisms to demyelination in MS (Lisak et al., 2012). The clear pathogenic role of B cells 
has been demonstrated by the positive results obtained by the administration of the B-cell 
depleting antibody Rituximab in RRMS patients (Carrithers, 2014).  
As mentioned before, B cells also have an immunoregulatory function: regulatory B cells 
(Breg) secrete the immunoregulatory cytokine IL-10, and a crosstalk between Bregs and 
Tregs has been shown. Bregs were proposed to have a role in autoimmune disorders 
(Fillantreau et al., 2002) as they inhibit Th1 differentiation and ameliorate arthritis in mice 
(Mauri et al., 2003; Brimnes et al., 2014).  
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Natural killer 
 
Natural killer (NK) cells are components of the innate immune system which fight pathogens 
directly by cell contact or indirectly by promoting an adaptive inflammatory response through 
T cells activation. NK cells express different levels of CD56, accordingly to their role: 
CD56
dim
 cells are highly cytotoxic and represent the majority of the circulating NK, while 
CD56
bright
 are immature NK with immunomodulatory functions. The latter have also been 
implicated in the beneficial effect of a drug used in the therapy of MS -daclizumab- 
(Bielekova et al., 2006). IFN-β, one of the earliest and most common treatments for MS, was 
also shown to induce the expansion of CD56
bright
 cell, which correlates to a positive clinical 
response (Martinez-Rodriguez et al., 2011; Hamann et al., 2013). However, while there are 
data suggesting a regulatory role of NK cells in MS, the mechanisms by which this is 
mediated are still unclear and further studies will be necessary to better understand the role of 
these cells in MS pathology. 
 
Macrophages/microglia 
 
MS lesions are characterized by different cells crossing the BBB and infiltrating the CNS. 
Among those cells infiltrating monocyte derived macrophages together with resident 
microglia play a crucial role in the initiation and progression of the disease (Lucchinetti et al., 
2000). The developmental origins of macrophages and microglia are distinct: macrophages 
derive from hematopoietic stem cells in the bone marrow, and subsequently become 
monocytes and differentiate into macrophages when they enter the tissue in response to 
inflammation; microglia come from hematopoietic cells in the yolk sac and migrate to the 
CNS during prenatal development before the BBB is formed (Prinz et al., 2014). Resident 
microglia make up for 5-15% of the total brain cell population, and take part to the initiation 
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and the progression of CNS inflammatory responses; they are also involved in the clearance 
of apoptotic cells, and in elimination and maintenance of synapses (Aguzzi et al., 2013). 
Microglia cells are considered poor antigen presenting cells as they normally express low 
levels of MHC class II. However, when activated microglia can participate in antigen 
presentation as evidenced by their increased expression of B7.2 and CD40 in the presence of 
IFN-γ and TNF-α (Carson, 2002; Kreutzberg, 1996; Becher and Antel, 1996).  
Macrophages can aquire different pro-inflammatory and anti-inflammatory phenotypes, 
which are respectively termed M1 and M2 macrophages. The distinction is based on different 
cytokine production, distinct inducing factors and on differences in phagocytic capability. M1 
macrophages classically express iNOS, CD16/32, and T-cell stimulating IL-12, while M2 
macrophages are characterized by expression of Arg1, CD206 and IL-10 (Liu et al., 2013). 
The polarization of macrophages into M1 or M2 phenotype depends on different 
environmental cues: IFN-γ and Toll-like receptor stimulating bacterial components promote 
differentiation into M1 macrophages, while IL-4, IL-13 and IL-10 polarize M2 cells (Deng et 
al., 2012).  Interestingly, macrophages are very plastic cells, which can sequentially show 
pro- and anti-inflammatory properties; their ability to switch between one phenotype and the 
other is rapid and reversible, and it can be modulated by removal and/or replacement of a 
cytokine (Porcheray et al., 2005). It was shown that in the animal model of MS, M1 and M2 
cells play a key role in the inflammation severity; in fact, M1 are predominantly present 
during relapses while administration of M2 macrophages attenuates the progression of the 
disease and increases the expression of immunomodulatory factors that promote recovery 
(Mikita et al., 2011).   
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Animal models of demyelination and inflammation 
 
The most extensively characterized animal model for autoimmune CNS inflammation is 
Experimental Autoimmune Encephalomyelitis (EAE), which was described for the first time 
in 1933 by Rivers and colleagues (Rivers et al., 1933).  EAE shares a lot of similarities with 
human demyelinating diseases, such as multiple sclerosis: the damage of myelin sheaths; the 
development of scattered lesions throughout the CNS and their perivascular location; the 
presence of immune cell infiltration and antibodies in the CNS and cerebrospinal fluid 
(Baxter et al., 2007).  EAE pathology and its clinical features depend on the animal species, 
in which it is induced; to date, EAE has been successfully reproduced in guinea pigs, rabbits, 
goats, hamsters, dogs, sheeps, marmosets, chickens, rats and mice (Freund et al., 1947; 
Olitsky and Yager, 1949; Tal et al., 1958; Thomas et al., 1950; Innes et al., 1951; Genain et 
al., 1995; Ranshoff, 2012).    
EAE is induced by immunisation with different myelin proteins, such as myelin basic protein 
(MBP), myelin oligodendrocytes glycoprotein (MOG) or proteolipoprotein (PLP), depending 
on the immunogenicity of such antigens in the different animals/strains (active EAE). Also, 
the model can be induced by adoptive transfer of T cells isolated from animals previously 
injected with myelin antigens (passive EAE). In active EAE, proteins are first emulsified in 
complete Freund´s adjuvant (containing Mycobacterium tuberculosis) and then animals 
receive one or two intraperitoneal injections with pertussis toxin e.g. at the day of 
immunization and 2 days after (Stromnes and Goverman, 2006a). Although both of models 
are known to be T cell mediated, passive EAE allows more manipulations to study the role of 
T lymphocytes; for instance, it is possible to label T cells before their transfer and therefore 
follow their localization and activity in the recipient mouse; another option is to manipulate T 
cells in vitro before transfer, allowing the study of specific T cells functions in the 
pathogenesis of EAE (Stromnes and Goverman, 2006b). 
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The EAE model has also proven to be useful to study the in vivo mechanisms of 
demyelination, axon damage, and especially CNS inflammation, thus allowing to define 
therapeutic targets for MS. More specifically, three major compounds used in the treatment 
of MS have been developed based on EAE studies: glatiramer acetate, mitoxantrone and 
natalizumab (Steinman and Zamvil, 2006).  
Nonetheless, despite its indisputable advantages, EAE has some important limitations. First, 
although few spontaneous EAE models do exist (Krishnamoorthy et al., 2006; 
Krishnamoorthy and Wekerle, 2009), in most cases it is an inducible disease, which makes it 
difficult to use it to shed light on MS etiology. Second, the multifactorial and complex 
pathogenesis of MS cannot be replicated in a single animal model, even though use of 
different animal strains or protocols can better model the numerous aspects of MS.   
In the classical EAE model, CD4+ T cells play a crucial role in the development of the 
pathology. C57/Bl6 mice are commonly used and are susceptible to immunization with a 
peptide from the myelin oligodendrocytes glycoprotein (MOG35-55). After induction of EAE, 
the mice manifest an ascending clinical paralysis, which progressively extends to hindlimbs 
and forelimbs. In such a disease paradigm, and in contrast to most MS cases, inflammatory 
lesions form predominantly in the spinal cord. This model is for example useful to study the 
contribution of specific CD4+ T cell subtypes to disease initiation and tissue damage. The 
finding that not only Th1 clones, but also Th17 cells can induce EAE (Cua et al., 2003), also 
led to insights in disease mechanisms, showing that inflammation dominated by Th1 or Th17 
lymphocytes substantially differ, with Th17-induced EAE showing not only limbs paralysis, 
but also ataxia, rolling, and proprioception defects (Jäger et al., 2009).  
EAE lesions are usually populated by a high number of phagocytes, which can derive from 
differentiated circulating monocytes or from activated microglia. This dichotomy was better 
elucidated by Ransohoff and his group who used a transgenic mouse model, which allows the 
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differentiation of monocyte-derived macrophages (MDMs) and microglia-derived 
macrophages (MiDMs). In these mice, MiDMs (Ly6C
lo 
monocytes expressing high levels of 
CX3CR1) express GFP, while MDMs (Ly6C
hi 
monocytes expressing high levels of 
chemokine receptor 2) are RFP positive (Saederup et al., 2010). This model allowed to 
describe density and recruitment dynamics of MDMs and MiDMs in the lesion area: while 
MDMs appear to be responsible for the detrimental demyelination process, which seems to 
start preferentially at the nodal and paranodal regions, MiDMS are involved in the removal of 
myelin debris (Yamasaki et al., 2014).   
As reviewed before in this thesis, B cells are also involved in the pathology of MS and their 
role has also been extensively studied in the EAE model. However their specific contribution 
to the disease process remains controversial as results substantially vary depending on the 
used EAE model. To study their contribution to EAE, both B cell deficient animals (µMT
-/-
) 
and anti-CD20 antibody mediated depletion have been used. After induction of EAE with 
recombinant MOG (known to activate B cells through their B cell receptor (BCR) and lead to 
their differentiation in plasma cells capable of producing antibodies against MOG), B cell 
depletion ameliorated the clinical symptoms of EAE, reduced anti-MOG antibody titers, and 
decreased the density of encephalitogenic Th1 and Th17. These findings would support a 
major proinflammatory role for B cells in the development of the disease. However, upon 
induction of EAE with MOG35-55 peptide (a model that doesn’t involve B cells activation), B 
cell depletion worsened the clinical course of the disease, possibly indicating that depletion of 
naive B cells is not beneficial (Weber et al., 2010; Simmons et al., 2013).   
EAE can also develop spontaneously in several mouse lines. These include a model of 
spontaneous opticospinal EAE which is characterized by demyelinating lesions in the spinal 
cord and in the optic nerve, resembling neuromyelitis optica (NMO) (Krishnamoorthy et al., 
2006), or SJL/J animals which recapitulate the major features of RRMS. The disease appears 
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spontaneously and usually takes a relapsing-remitting course, showing lesions not only in the 
spinal cord but also in cerebellum, brainstem and optic nerve (Pöllinger et al., 2009). These 
lesions are composed of T cells, macrophages/microglia, B cells, activated complement and 
antibodies (Berer et al., 2011).  
Relapsing-remitting EAE can also be induced in C57/Bl6 mice by immunization with low 
dose of MOG35-55 (Berard et al., 2010), or when the saponin extract Quil A is used as 
adjuvant (Peiris et al., 2007).   
Secondary progressive MS can for example be studied in BiozziABH animals. This strain 
was described for the first time in 1972 by Guido Biozzi, who reported that these mice had 
high antibody titers in response to specific antigens (Biozzi et al., 1972). Following 
immunization with myelin antigens, these mice initially develop a relapsing-remitting EAE 
which evolves into a steady clinical progression. Demyelination is particularly strong during 
the relapses, and the lesions are associated with the presence of macrophages, CD4+ T cells 
and immunoglobulin deposition (Baker et al., 1990; Amor et al., 2005).   
Histopathologically, the pattern of CNS damage of the models described above resemble 
lesion pattern I and II of MS, in which infiltrates are mainly composed by T cells and 
macrophages, and with a strong involvement of antibodies and complement deposition 
(Lucchinetti et al., 2000). To model pattern III and IV, characterized primarily by 
oligodendrocytes degeneration and apoptosis, administration of toxins or solvents such as the 
copper chelator cuprizone or lysophosphatidylcoline respectively, have been used. 
Furthermore, these models are particularly interesting for remyelination studies (Lucchinetti 
et al., 2000; Ransohoff, 2012; Simmons et al., 2013). 
Lastly, it is important to remember that while the EAE models described till now mainly 
elicit CD4+ T cells response, it is known that CD8+ have an important role in the 
pathogenesis of the human disease, being the majority of the T lymphocytes present in the 
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MS lesions (Babbe et al., 2000). Adoptive transfer of MBP-specific CD8+ clones resulted in 
the development of EAE; however, the disease induced by CD8+ T cells seems different 
from the CD4+ induced EAE, with the majority of the lesions located in the brain and not in 
the spinal cord. Further they show extensive demyelination and significant oligodendrocytes 
death, resembling more pattern III and IV (Huseby et al., 2001).  
 
Treatment of MS 
 
As reviewed in paragraph 1.4 of this thesis, the pathogenesis of MS involves the infiltration 
and local activation of different immune cell types, which are the main targets for the 
treatment of the disease. To date, there are 12 drugs available in the majority of the countries 
(approved e.g. by the U.S. Food and Drug administration -FDA-) to treat MS, and those are 
aimed at managing the symptoms, preventing relapses and slowing disease progression: 
interferon β-1a and β-1b (Avonex, Plegridy, Rebif, Betaseron, Extavia), glatiramer acetate 
(Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), alemtuzamab (Lemtrada), 
fingolimod (Gilenya), teriflunomide (Aubagio), dimethyl fumarate (Tecfidera) 
(http://www.nationalmssociety.org/) (Figure 3).    
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Figure 3 - MS treatments. The figure illustrates the targets of action of the drugs used in the therapy of 
MS. Some of these drugs act on both T lymphocytes and B cells, including mitoxantrone, 
alemtuzumab and teriflunomide. Others are specific for T cells, such as IFN-β, glatiramer acetate and 
natalizumab, while rituximab works only on B cells. Daclizumab and FTY720 specifically exert their 
function respectively on NK cells and T lymphocites in the LN. 
 
The first widely used treatments for MS were interferon β (IFN-β) and glatiramer acetate. 
The mechanisms of action are not fully clear, but most likely they act on T cells, decreasing 
their number and interfering with their activation, as well as stimulating Treg and IL-10 
response (Bashir and Whitaker, 1998).  Interferons (IFNs) are proteins secreted in response to 
pathogens, and their job is to modulate the immune response. The type I IFNs include IFN-α 
and IFN-β, and they have anti-inflammatory properties. On the other hand, type II IFNs 
include IFN-γ, which has pro-inflammatory activity. In therapy IFN-β1a and IFN-β1b are 
used, which have similar biological effects and similar side effects. The former involve i) 
modulation of T cell activation by inhibition of upregulation of MHC II molecules induced 
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by IFN-γ (Panitch et al., 1987), ii) enhanced secretion of IL-10 and reduced IL-12 (Wang et 
a.l, 2000), iii) inhibition of metalloproteinase 9 (which digests matrix membrane and 
favourites entrance of cells into the CNS through the BBB) production by T cells, and 
therefore decreased openings of the BBB (Stuve et al., 1996). The latter are injection site 
reactions, anaemia, flu-like symptoms, fever and depression. Glatiramer acetate (GA) is a 
synthetic polypeptide composed of 4 aminoacids that shares some crossreactivity with the 
structure of the possible MS autoantigen myelin basic protein (MBP). It is able to inhibit 
MBP-reactive T cells and to preferentially induce Th2 activation (Dhib-Jailbuts, 2002). Both 
GA and IFNs are used in the treatment of RRMS and are self-injectable drugs, which need to 
be administrated either subcutaneously or intramuscular very frequently (every other day for 
IFN-β1b, weekly for IFN-β1a, and daily for GA) (Wingerchuk and Carter, 2014).  
Another drug used in RRMS is mitoxantrone that also shows some effect in the treatment for 
SPMS. Mitoxantrone was originally developed as an anti cancer agent; it inhibits 
proliferation of dividing cells including lymphocytes and its mechanisms of action include its 
ability to intercalate in the DNA causing strand breakage (Marriott and Miyasaki, 2010). Due 
to its strong side effect, in particular the higher risk of cardiomyopathy, the use of this 
treatment is restricted to a maximum of 2 years (Wingerchuk and Carter, 2014).  
Natalizumab was approved for the first time as treatment for RRMS in 2004. It is a 
monoclonal antibody against the α-4 chain of the α4β1 integrin on leukocytes surface and 
prevents the interaction with vascular cell adhesion molecule-1 (VCAM-1), therefore 
blocking T cells trafficking across the BBB (Barten et al., 2010). It has been shown that in 
patients that received 24-36 months of intravenous natalizumab, there is a higher risk of 
developing progressive multifocal leukoencephalopathy (PML); this is a rare neurological 
disorder caused by the John Cunningham virus (JC) which leads to irreversible disability and 
often to death (Kleinschmidt-DeMasters et al., 2005). 
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Alemtuzumab is a humanized monoclonal antibody against CD52, a protein expressed on 
monocytes and lymphocytes. Its effects are rapid and induce a broad lymphocytes depletion: 
while B cells repopulate in 5-6 months, T cells -in particular CD4+ T cells- remain depleted 
up to 1 year (Cossburn et al., 2011; Wingerchuk and Carter, 2014). It is injected 
intravenously for 5 consecutive day cycles in a month, and later 3 consecutive days at 12 and 
24 months. In a study aimed to compare the benefits of alemtuzumab versus IFN-β1a, 
alemtuzumab was more effective with substantial reduction of disability and fewer relapses 
compared to the patients treated with IFN-β1a (The CAMMS223 Trial Investigators, 2008). 
However, it is associated with strong side effects: at least 20% of patients developed 
antibody-mediated autoimmune diseases, and roughly 3% immune thrombocytopenic 
purpura, as well as hyper or hypothyroidism (Cossburn et al., 2011).  
The medications described above are all administered intravenously, subcutaneously or 
intramuscularly, therefore causing injection site reactions. In the past years the FDA 
approved three oral treatments for relapsing MS: fingolimod, terifluonomide, and dimethyl 
fumarate.  
Fingolimod (FTY720) modulates the S1P1 receptor. This receptor is expressed on 
lymphocytes and it is responsible for the exiting of lymphocytes from the lymph node. As a 
result, lymphocytes are trapped in the lymph nodes and cannot enter the CNS and form 
lesions (Barten et al., 2010). Fingolimod is a daily treatment and it seems to be more efficient 
compared to IFN-β1a (Cohen et al., 2010). It is not free of adverse effects too, which are 
mainly related to lymphopenia, such as an elevated risk of viral infections. It is also important 
to keep in mind that the S1P1 receptor can be expressed by other cell types, thus leading to a 
broader spectrum of potential side effects including bradycardia, macular edema, or 
hypertension (Wingerchuk and Carter, 2014). 
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Teriflunomide is an inhibitor of dihydroorotate dehydrogenease, and enzyme responsible for 
the synthesis of the pyrimidines in proliferating cells. The final effect is the inhibition of T 
and B cell activation, thereby reducing the inflammation. Teriflunomide is also able to block 
protein tyrosine-kinases and modulate the production of cytokines and expression of cell 
surface molecules. It is an oral drug that needs to be taken once a day; it is well tolerated by 
patients, who usually refer to its side effects as mild or moderate. The higher risk is 
represented by its teratogenicity, which makes it an unsuitable medication for pregnant 
women; it also has a long half-life, and it takes up to 2 years to fully clear this drug (Barten et 
al., 2010; Oh and O’Connor, 2013).  
The latest commercially available oral treatment for multiple sclerosis is dimethyl fumarate. 
Its mechanism of action is still not fully described, but it is believed to reduce oxidative stress 
and protect axons (Albrecht et al., 2012). It was recently suggested that dimethyl fumarate 
active metabolite (monomethyl fumarate) acts as agonist of the hydroxycarboxylic acid 
receptor 2 (HCA2), a G protein coupled membrane receptor expressed by immune cells and 
expecially by neutrophils (Chen et al., 2014). The administration of dimethyl fumarate is two 
times per day; it is used in RRMS patients, which show a significant reduction in the 
frequency of relapses and in the size lesions. It is quite well tolerated, with the main adverse 
effect be flushing and gastrointestinal symptoms (Barten et al., 2010).  
Other treatments are under investigation. Among those, the monoclonal antibodies rituximab 
and daclizumab. The rituximab antibody targets the CD20 protein expressed on B cells and 
leads to their depletion; while it seemed to reduce the relapse rate in RRMS patients, it did 
not give positive results on PPMS. Rituximab is not yet approved as a treatment for MS; 
however, there is an increasing interest in developing new drugs that target B cells, especially 
in secondary progressive MS (Carrithers, 2014). Ocrelizumab, for example, is another anti-
CD20 antibody structurally similar to rituximab that is currently studied in advanced clinical 
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trials. A different, and novel, target are natural killer cells: in fact, daclizumab is an antibody 
against CD25 that stimulates CD56
bright
 cells; first studies show its efficacy in improving 
clinical symptoms and reducing lesions (Barten et al., 2010).  
 
2. Oligodendrocytes physiology and pathology 
 
Oligodendrocytes physiology 
 
Oligodendrocytes are glial cells of the CNS; their main role is to form myelin around the 
axons and therefore allow a fast transmission of the nerve impulse. However, this is not their 
only function in the CNS; as I will briefly review in this paragraph, they play multiple 
important roles in supporting axon integrity and function. 
The origins of oligodendrocytes in the spinal cord are different from those in the brain. The 
oligodendrocyte precursor cells (OPCs) in the spinal cord arise from the ventral 
neuroephitelium; the first wave of OPCs production starts at embryonic day 12.5 (E12.5), 
which is then followed by a second wave at E15.5 and a third one after birth. On the contrary, 
the first wave of OPCs in the brain starts ventrally at E12.5, but it is soon replaced by more 
dorsally generated precursors; second and third waves are generated from the lateral and 
caudal ganglionic eminences (Mitew et al., 2014).   
OPC differentiation comprises different stages defined by sequential expression of 
developmental markers and changes in proliferative capacity, migratory ability, and 
morphology. Few genes have been recognised as necessary for a correct differentiation: 
Olig2 and Olig1, for instance, represent important regulators of oligodendrocytes (OLs) 
development. Olig2 is expressed throughout the entire differentiation, while Olig1 is 
predominantly present during the transition between preOLs and OLs (Rowitch, 2004; 
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Silbereis et al., 2010). Other signaling pathways are involved in OLs development, such as 
bone morphogenetic protein (BMP), Wnt, Notch, and sonig hedgehog (Fancy et al., 2010).  
OPCs are characterized by the expression of platelet-derived growth factor-α receptor 
(PDGFαR) and chondroitin sulfate proteoglycan NG2, and other markers; these proteins are 
down-regulated when the progenitors reach their final destination in the spinal cord or in the 
brain. At this point, the OPCs differentiate into mature oligodendrocytes (also called 
premyelinating oligodendrocytes, preOLs) and later into myelinating oligodendrocytes 
(OLs); the later ones express high level of myelin proteins, such as PLP, MBP, and also 
APC-CC1. When the OL is capable of myelinating axons, its morphology changes showing 
more elaborated processes. (Figure 4). 
As mentioned already, a key function of OLs is to myelinate axons. The study of myelin 
biology started in 1717 when Leeuwenhoek, who was interested in the observation of plants 
and animal tissue using self-made microscopes, reported: “Sometimes I observe nervule to be 
completely surrounded by fatty parts”. According to Cajal, the credit for myelin discovery 
goes to Ehrenberg in 1833, who described nerve fibers consisting of cylindrical tubes. After 
him, a lot of scientists took interest in nerve fibers, but Ranvier was the first one, in 1871, to 
realize that myelin sheaths are periodically interrupted and discontinuous. The development 
of electron microscopy finally allowed to characterize the “fatty parts” described 200 years 
before, as concentric membranes belonging to OLs, and not secreted by the axon as 
hypothesized by Cajal in 1909. The role of myelin in allowing saltatory signal conduction in 
axons was eventually revealed by Huxley and Staempfli in 1949 (Rosenbluth, 1999).  
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Figure 4 - Oligodendrocyte differentiation and markers expressed. The different stages in the 
maturation of an OL can befined based on the expression of specific markers. Although some of them 
are specific for OPC or myelinating OL, some others like Olig2 or Sox10 are present throughout the 
entire developmental process.  
  
It is now known that a single OL can form up to 80 internodes on different axons, a feature 
with regional variations that also depends on axon diameter: the bigger the diameter, the 
thicker the myelin will be, and the less internodes will be formed by the OL (Snaidero and 
Simons, 2014). 
Myelin, named so by Virchow in 1854, is a periodic structure, in which electron-dense lines 
alternate with light layers, and it is the main component of CNS white matter. Its dry weight 
consists of 70% lipids and 30% proteins. Among these proteins, myelin basic protein (MBP) 
is the one of the most abundant. In mice with a deletion of MBP gene, the dense line in 
myelin structure is missing, thus revealing an important role of MBP in myelin compaction 
(Privat et al., 1979). Another major component of myelin, corresponding to 50% of all 
myelin proteins, is the proteolipid protein (PLP); it is a tetraspan membrane protein which is 
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an important stabilizer of the membrane junction after myelin compaction (Nave, 2010). 
MBP and PLP are the main components of myelin, but there are other well characterized 
proteins: CNP (4% of total myelin proteins) is a protein that hydrolyzes 2’,3’-cyclic 
nucleotides into their 2’-derivates, it is localized not only on myelin but also on retina 
photoreceptor, and it was demonstrated that it is involved in cytoskeleton reorganization and 
arborization of OLs processes (Lee et al., 2005); MAG (1% of the total proteins), mainly 
localized in the paranodal region, is not part of the compact myelin and belongs to the 
immunoglobulin superfamily; and MOG, whose presence correlates with the late stages of 
maturation, is restricted to myelinating OLs and located on the outermost layers of compact 
myelin. MOG is widely used to induce EAE and which can trigger both T-cell mediated and 
antibody-mediated responses (Baumann and Pham-Dinh, 2001) (Figure 5).  
CNS myelination is a long process starting postnatally and reaching completion in mice 
around 40-60 days of age. In the human CNS, it starts during fetal life in the spinal cord and 
it reaches its maximum peak in the first year of life (Baumann and Pham-Dinh, 2001). 
However, OPCs continue to differentiate into mature OLs also during adulthood. A recent 
study demonstrated further that these newly formed OLs are mainly involved in myelin 
remodelling and plasticity rather than de novo myelin formation. Also, the configuration of 
the internodes are different, in fact late-born OLs generate more and shorter internodes than 
early-born OLs (Young et al., 2013). Compared to rodents, the OLs in humans are less 
dynamic, with a 100-fold lower generation rate (0.32%/year in humans versus 36.5%-
186%/year in adolescent and adult mice) (Yeung et al., 2014). 
Once the oligodendrocyte process has contacted the axon it progresses to myelinate in a 
spiralling way. This progression has been the subject of multiple studies: Bunge et al. 
proposed that the oligodendrocyte membrane extends along the entire internode and then 
starts to myelinate the axon, with the inner tongue rolling underneath the previously 
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generated layers of myelin and all the layers running parallel to the axon axis (“Carpet 
crawler” model) (Bunge et al., 1961). However, we now know that within a single internode, 
the number of myelin leaflets can vary. This led to the  suggestion of the “serpent model”, 
according to which a single process contacts the axon and starts to turn around it; when it has 
reached the desired number of turns, the layers will start to grow laterally and slide one onto 
each other (Pedraza et al., 2009). The “liquid croissant” model (Sobottka et al., 2011) came a 
couple of years later, and it suggests that the outer layers are added in a croissant-like manner 
on the inner layers. Lastly, recent improvements in electron microscopy allowed to describe a 
new myelination model, in which the leading edge at the inner tongue continuously wraps 
around the axon, while the formed myelin layers expand laterally towards the nodal region 
(Snaidero et al., 2014; Snaidero and Simons, 2014).  
The function of OLs in the CNS is not only restricted to myelin production; two recent 
publications have brought attention to their role in supporting axonal energy metabolism. 
Myelinated axons appear to have limited access to extracellular energy substrates; however, 
they require a lot of energy metabolites like glucose and lactate. The works from Lee et al. 
and Fünfschilling et al. suggest that OLs can produce lactate and are able to transfer it 
directly to the axons: OLs express MCT1 (monocarboxylate transporter-1, implicated in the 
transport of lactate, pyruvate and ketone bodies) and, through interaction with MCT2 on 
axons, are able to transfer lactate (or pyruvate) to neurons, and therefore support axonal 
integrity (Lee et al., 2012; Morrison et al., 2013; Fünfschilling et al., 2012).  
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Figure 5 - Proteins of the myelin sheath. Myelin is a highly compact structure composed by lipids 
(70% of the total dry weight) and proteins (30%). Among those proteins, the major components are 
myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocytes glycoprotein (MOG) 
and myelin associated glycoprotein (MAG).  
 
 
Oligodendrocytes damage in MS and EAE 
 
MS and its animal model EAE are believed to be primarily demyelinating diseases, in which 
OLs and their myelin sheaths appear to be the main targets of the inflammatory reaction. 
Recent studies have however brought attention to axonal pathology, which can occur 
independently of the myelination status of the axon, thus implying that axons may also be a 
primary target of the immune attack (Nikić et al., 2011). 
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Oligodendrocytes can in principle be damaged in different ways. One possibility is that OLs 
death can be induced by oxidative damage. OLs are particularly vulnerable to oxidative stress 
for several reasons: 1) they need to synthesize and maintain a large amount of myelin, and 
this requires energy; therefore OLs produce a lot of ATP and consequently hydrogen 
peroxide (a toxic byproduct of ATP synthesis), which –if not metabolized correctly- can lead 
to DNA degradation and OLs death (Wosik et al., 2003); 2) OLs store iron in large quantities 
because it is required for myelin production; however, iron is also very reactive and can 
evoke the production of free radicals and lipid peroxidation (Todorich et al., 2009); 3) OLs 
have low concentrations of the antioxidant enzyme gluthatione (Juurlink et al., 1998; 
McTigue and Tripathi, 2008). Indeed, it has been shown that reactive oxygen species can 
damage myelin sheaths, as well as axons (Haider et al. 2011; Nikić et al., 2011) and 
components of the blood-brain-barrier (Rubanyi, 1988), and that ROS scavenger can prevent 
myelin phagocytosis (van der Goes et al., 1998).  
OLs are also susceptible to excitotoxicity that is most commonly induced by excessive 
glutamate. The resulting overactivation of AMPA and kainate receptors on OLs can in fact 
lead to OLs injury and death. Studies have shown that the treatment of EAE animals with 
AMPA/kainate antagonists (such as NQBX or MPQX) improves the clinical scores and 
increases OLs survival (Pitt et al., 2000; Smith et al., 2000; Matute et al., 2001).  
Another pathway of excitotoxic cell death is induced by extracellular ATP, the concentration 
of which is significantly higher at sites of injury. Its receptor P2X7 is expressed by 
oligodendrocytes and it is highly permeable to Ca
2+
. In EAE, it was therefore suggested that 
the sustained activation of P2X7 receptor by ATP is lethal for OL and that the application of 
P2X7 antagonist ameliorates the motor deficits and reduces demyelination (Matute et al., 
2007).  
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With regards to OL damage in MS, the sequence of events that leads to demyelination 
remains an open question. In fact, given their morphology, OLs can be attacked at different 
sites. They can be targeted at the cell body, in which case the damage will spread towards the 
myelin sheath, or vice versa myelin can be the main target and the damage will then move 
towards the soma.  
On the one hand, Lucchinetti at el. have suggested that in rare cases, lesions are mainly 
characterized by OLs damage (pattern III and IV). Particularly in pattern IV lesions, OLs are 
the primary target and they undergo degeneration and apoptosis, while demyelination appears 
to be only a secondary process (this sequence would represent an “inside-outside” gradient of 
demyelination) (Lucchinetti et al., 2000; Lassman et al., 2001). The hypothesis that OLs 
death can be a major hallmark of MS pathology is supported by another study that described 
the formation of new lesions. Here the authors suggest, that the first step involves apoptosis 
of OLs with no myelin phagocytosis, which appears only in the final stages of lesion 
formation (Barnett and Prineas, 2004). Experimental models of primary OLs pathology may 
therefore be useful to explain the role of OLs and their death in MS.  Different transgenic 
mice have been recently generated to selectively kill OLs in vivo in which either diphtheria 
toxin receptor (DTR) or diphtheria toxin fragment A (DTA) are expressed by 
oligodendrocytes (i.e. MOGiCreiDTR mice, MBP-DTR mice or PLPCreER
T
:ROSA26-
eGFP-DTA), and the administration of diphtheria toxin or the activation of DTA triggers OLs 
paralysis and death. In these models, demyelination is delayed in respect to OLs death, which 
probably means that myelin can survive for few weeks even without the support of the 
connected OL (Traka et al., 2010; Locatelli et al., 2012); in the MBP-DTR mouse it appears 
that myelin damage is restricted only to the nodal region, with paranodal loop eversion and 
redistribution of nodal proteins (Oluich et al., 2012). Other models have been proposed to 
study the effect of OLs death, like for example the one suggested by Capriariello et al. who 
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created a novel mouse model in which a lentiviral construct expressing inducible caspase 9 
(iCP9) under the control of a MBP promoter efficiently leads to OLs apoptosis. Interestingly, 
in these animals OLs apoptosis stimulated local microglia activation and rapid demyelination 
(Caprariello et al., 2012).   
On the other hand, in other MS lesions subtypes (pattern I and II) described as the most 
common patterns (Lucchinetti et al., 2000), myelin itself seems to be the primary target of 
tissue destruction and demyelination would follow an “outside-inside” gradient. The 
assumption that myelin is the primary target is not surprising considering that many myelin 
proteins can serve as autoantigens in MS and thus lead to primary inflammatory 
demyelination. MOG is localized at the outermost layer of the myelin sheath; its role as a 
potent autoantigen in the pathogenesis of EAE has been clear for several years, and it is 
known that anti-MOG antibodies can induce demyelination. The conformation of the antigen 
also plays a role to determine its encephalitogenicity: for example, re-folded MOG seems to 
be more pathogenic than its non-refolded counterpart, with conformational MOG antibodies 
found in the serum of rats immunized with refolded MOG and strong T-cell response 
induction (de Graaf et al., 2012). Antibodies against MOG have also been reported in 
pediatric cases of MS, but are not commonly detected in adult patients (Pröbstel et al., 2011). 
PLP and MBP are other candidate autoantigens, considering also their pathogenic role in the 
development of EAE in specific laboratory mouse strains. Anti-PLP antibodies as well as 
autoimmune PLP-specific T cells reactive with PLP have been found in MS patients. Anti-
MBP antibodies have been detected in close proximity to injured axons within a lesion, and 
are thought to specifically damage myelin membrane inducing therefore demyelination 
(Derfuss and Meinl, 2012; Quintana et al., 2012).  
The nodal region can also be a starting point for demyelination and this possibility has raised 
quite some interest over the past years. The nodes of Ranvier are short unmyelinated regions 
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of the axons where Na
+
 enters to generate action potentials. The nodal area includes the node 
of Ranvier itself, the paranodal segment and the juxtaparanodal region. The node of Ranvier 
is characterized by a high density of Na
+
 channels (Nav1.1, Nav1.6) and some K
+
 channels 
(Kv); a large number of scaffolding and adhesion proteins, such as ankyrin G and neurofascin 
186 (NF186), are also clustered in this area. In MS and EAE the nodes appear longer and this 
might be associated with a retraction of the myelin sheath and the disruption of the paranodal 
area (Fu et al., 2009). The paranode is defined as the region where myelin loops are in 
contact with the axons, and it is located at both sides of the node; the proteins which 
dominate this area are contactin-1 and contactin associated protein-1 (Caspr1), and 
neurofascin 155 (NF155) on the myelin membrane. This appears to be a very vulnerable 
structure as it has been shown that in demyelinating diseases the myelin loops of the 
paranode appear loose and the proteins arrangement is disorganized. Interestingly, 
autoantibodies against NF155 and NF186 have been found in MS patients, and in the same 
study it was shown that these antibodies exacerbate the clinical course of EAE in a rat model 
of T-cell transfer EAE (Mathey et al., 2007). Lastly, the juxtaparanodal region is populated 
by K
+
 channels (Kv1.1 and Kv1.2), adhesion molecules (contactin-2/TAG-1 and Caspr-2), 
and metallopreotease (ADAM22). Contactin2/TAG-1 has also been recognised as a potential 
autoantigen for autoantibodies and T cells activation in MS patients (Meinl, 2011; Derfuss et 
al., 2009; Simons et al., 2014).  
 
Oligodendrocyte repair and remyelination  
 
Remyelination is defined as the process of generating new myelin sheaths around a 
previously demyelinated axon. In 1979 Smith and colleagues showed for the first time that in 
remyelinated axons conduction is restored, which prompted subsequent studies to investigate 
mechanisms that can improve remyelination (Smith et al., 1979). Remyelination is indeed an 
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important recovery process; firstly because it helps axonal survival and protects them from 
further degeneration (Irvine et al., 2008), and secondly because by reorganizing the nodes 
and paranodes with their voltage dependent channels it restores appropriate saltatory 
conduction of action potentials.  
One way to identify remyelination is to measure the g ratio, which is the ratio between the 
diameter of the axon and the myelin thickness: remyelinated axons show a thinner and shorter 
myelin sheath, resulting in a higher than normal g ratio. The average g ratio of a myelinated 
axon is between 0.6 and 0.8, while a remyelinated axon typically has a g ratio of 0.8-1 (Olsen 
et al., 2014). (Figure 6). 
Remyelination is a multistep process triggered by demyelination. Following injury in fact 
OPCs become activated and respond to pro-migratory and mitogen factors that induce their 
migration and proliferation to the site of injury. Once they reach the demyelinated lesion, 
OPCs change morphology and differentiate into mature myelinating cells, which ultimately 
will remyelinate the area.   
Remyelination is initiated by the generation of new OLs derived by a population of precursor 
cells; in adulthood, these cells are widespread in the white and gray matter in the CNS, and 
can be recognized by the expression of markers such as NG2, PDGFRa, Olig2, Olig1 and 
more. Few studies have shown that those OPCs are the main source of remyelinating OLs by 
the use of in vitro and transplantation approaches describing OPCs being able to differentiate 
into OLs and remyelinate areas of demyelination (Groves et al., 1993; Nunes et al., 2003). 
Also, demyelinated areas during remyelination display cells that express both OPCs and OLs 
markers (Fancy et al., 2004).  Recently it has also been suggested that NG2+ precursors 
constantly migrate through the adult brain and can directly differentiate into mature OLs 
without proliferating; interestingly, it seems that these cells also participate in the glial scar 
 
Introduction    -    32 
 
formation extending their processes toward the lesion site and surrounding the site of injury, 
as it was observed by time-lapse in vivo imaging (Hughes et al., 2013).  
Figure 6 - g-ratio of myelin sheaths in relation to axon diameters. Inspired by Olsen et al., 2014. 
 
New OLs can also derive from cells in the subventricular zone (SVZ), either from precursor 
cells involved in the rostral migratory stream or from GFAP-expressing stem cells. These 
cells are for example the major contributers to remyelination in the corpus callosum 
following damage to myelin structure (Franklin and ffrench-Constant, 2008).  
The regulation of OPCs differentiation from pre-myelinating cells to myelinating OLs 
depends on different intrinsic and extrinsic factors. Among the intrinsic factors, there are both 
positive and negative regulators. An example of a positive regulator is the myelin gene 
regulatory factor (MRF) which is essential for OPCs differentiation into MBP-positive and 
MOG-positive OLs (Emery, 2010). Zinc finger protein 191 (Zfp191) is also important for 
myelination; in mice, the mutation of Zfp191 causes hypomyelination with OLs that appear 
functional, but are not capable of myelinating axons (Howng et al., 2009). Retinoid X 
receptor-γ (RXR-γ) was found to be upregulated during remyelination in a rat model of 
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demyelination, and its pharmacological stimulation enhanced remyelination. RXR-γ 
expression was also detected in MS lesions, and it was mainly localized in the nucleus or 
cytosol of Olig1+ precursors (Huang et al., 2011). Important to mention are the Notch-
Jagged1 and the Wnt signalling pathways. The former has an inhibitory role on OPCs 
maturation and its pharmacological block in EAE enhances recovery and myelin repair 
(Jurynczyk et al., 2005; Luessi et al., 2014). The latter negatively regulates myelin formation 
as well, making it a good target for therapeutic studies. OPCs differentiation is also regulated 
by extrinsic factors, either secreted by neurons or by macrophages/microglia. Those are for 
example bone morphogenetic protein 4 (BMP4) or Lingo-1, both working as inhibitors of 
OPCs maturation. Interestingly recently an important role for macrophages/microglia during 
remyelination has been proposed based on the demonstration that macrophages switch from 
M1 to M2 phenotype at the time of remyelination. M2 macrophages then promote OLs 
differentiation by production of activin-A. In line with these findings M2 depletion resulted 
in a lower oligodendrocyte differentiation rate (Miron et al., 2013).  
Once the OLs are differentiated into myelinating cells, they can contact axons and wrap 
around their processes to form a new myelin sheath. However, we know that remyelination 
does not work efficiently in MS.  One possible explanation of why remyelination fails might 
be that OPCs cannot repopulate properly and are low in number; however, this idea is most 
likely to be excluded because it has been described that OPCs can efficiently migrate to the 
lesion site (Aguirre et al., 2007; Fancy et al., 2004; Nakatani et al., 2013). A second failure 
mechanism might be that OPCs are not correctly recruited and therefore do not reach and 
differentiate in the demyelinated area.  In support of this idea it has been shown that MS 
patients can have autoantibodies against NG2, providing evidence that OPCs can also be a 
target of autoimmune attack in MS (Niehaus et al., 2000). The last, and probably the most 
accurate, hypothesis is that OPCs migrate and proliferate, but do not differentiate into 
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myelinating cells. One explanation might be that the demyelinated areas contain factors that 
inhibit their differentiation (such as Notch-Jagged1 or Wnt) (Franklin and ffrench-Constant, 
2008; Franklin and Gallo, 2014). 
 
3. In vivo imaging 
 
Principles of two-photon excitation microscopy 
 
Multi photon microscopy is a nonlinear optical microscopy technique suited for high 
resolution imaging of physiological processes, morphology and cell-cell interactions in tissue 
and living animals. It was theoretically described for the first time in 1931 in a doctoral thesis 
by Maria Goeppert-Mayer, but experimentally verified only in 1990 (Denk et al., 1990). 
The principle of two photon microscopy lies in the excitation of a fluorescent molecule by the 
simultaneous absorption of two photons of equal energy, the total energy of which is the 
same as the one required for a single photon excitation of the flurophore. Once the molecule 
reaches the excited state, the emission is the same in one photon and two photon excitation 
(Figure 7a).  
Two-photon imaging has become the most popular technique for in vivo imaging, and it 
presents numerous advantages. First, while in standard one-photon microscopy the excitation 
process requires photons in the ultraviolet/blue/green spectral range, multiphoton absorption 
occurs in the near-infrared wavelength range; near-infrared light has the advantage of 
allowing a  deeper penetration into the tissue (up to 1000um), reducing phototoxicity and 
minimizing photobleaching. Second, multiphoton absorption is restricted to the focal plane 
and there is no out-of-focus excitation, in contrast to standard single-photon excitation, where 
the fluorescence signals are generated above and below the focal plane (Zipfel et al., 2003; 
Helmchen and Denk, 2005) (Figure 7b). 
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The setup of a two-photon microscope is similar to a single-photon confocal laser scanning 
microscope; the main difference is the presence of a pulsed laser source, most typically a 
Titanium-sapphire (Ti:Sapphire) oscillator, which provides ultrashort (femtoseconds or 
picoseconds) near-infrared pulses at high repetition rate (100 MHz). The wavelength is 
tuneable usually in the range of 670nm-1040nm, allowing the two photon excitation of a 
broad spectrum of fluorophores (Diapstro et al., 2006; Helmchen and Denk, 2005).    
Figure 7 – Principles of one-photon excitation versus two-photon excitation. a) Jablonski diagram 
illustrating one- and two-photon excitation of a fluorophore from the ground state to the excited state; 
b) on the left, blue light is used to excite in one-photon microscopy, and the excitation generates a 
cone of fluorescent light; on the right, near-infrared light is used to excite in two-photon microscopy, 
and there is not out-of-focus signal. Inspired by Helmchen and Denk, 2005. 
 
 
Imaging the healthy and diseased central nervous system 
 
In vivo imaging has become a powerful tool in neuroscientific research: it allows to directly 
follow cell dynamics, to observe the same cell over the time and see how it changes in 
response to an injury, and to study how different cells interact with each other. Imaging in the 
CNS is performed in the brain by implanting a cranial window or by the thinned skull method 
(Grutzendler et al., 2002; Zuo et al., 2005; Xu et al., 2007; Holtmaat et al., 2009; Yang et al., 
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2010); these techniques are useful to visualize the same area at different timepoints within the 
same experiment, allowing chronic imaging sessions. When it comes to the spinal cord, acute 
imaging sessions are the most common; however, repetitive imaging is also possible, and 
recent spinal cord windows have been developed (Farrar et al.,2012; Fenrich et al., 2012).   
Advances in microscopy techniques go hand in hand with advances in labelling techniques. 
The discovery that indisputably changed labeling strategies was the introduction of the 
jellyfish green fluorescent protein (GFP) as a vital stain (Chalfie et al., 1994). The first report 
used GFP to label neurons (Chalfie et al., 1994), but in the following years GFP (and its 
spectral variants yellow [YFP], cyan [CFP], red [RFP] fluorescent proteins) technologies 
were extensively applied to generate transgenic mice that express the fluorescent proteins 
under different promoters in order to drive the labelling to specific cell types of interest 
(neurons, glial cells, immune cells,..) or organelles (mitochondria, peroxisomes, 
microtubules,..) (Table 1).  
Neuroscientists have used these in vivo imaging approaches to study calcium dynamics 
(Svoboda et al., 1997; Helmchen and Waters, 2002), neuronal plasticity (Svoboda et al., 
1996), as well as neurological diseases (Misgeld and Kerschensteiner, 2006; Sorbara et al., 
2012). The use of in vivo imaging and transgenic mice is particularly useful to unravel the in 
vivo pathogenesis of neurological disorders such as Alzheimer’s disease (Fuhrmann et al., 
2010; Kuchibhotla et al., 2008; Busche et al., 2008), ischemia (Nishimura et al., 2006; 
Sakadzic et al., 2010), injury (Nguyen et al., 2002; Kerschensteiner et al., 2005) and multiple 
sclerosis. The latter has been the subject of a number of studies aiming at understanding on 
one hand recruitment, trafficking, function and activation of T cells (Bartholomaus et al., 
2009; Siffrin et al., 2009; Mues et al.., 2013), and on the other hand mechanisms of axonal 
loss (Siffrin et al., 2010; Nikić et al., 2011); a recent publication also raised interest in the role 
of mitochondrial transport deficits (Sorbara et al., 2014). 
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Cell type Promoter Fluorescent protein Reference 
Neurons Thy1-promoter XFP Feng et al., 2010 
Neuronal 
mitochondria 
Thy1-promoter, with 
mito targeting 
sequence 
CFP Misgeld et al., 2007b 
Oligodendrocytes PLP-promoter GFP Mallon et al., 2002 
Schwann cells S100-promoter GFP, YFP Zuo et al., 2004 
Astrocytes 
GFAP-promoter 
Aldh1L1-promoter 
GFP 
Zhuo et al.., 1997 
Gong et al., 2003 
Microglia * Cx3CR1-locus GFP, YFP Jung et al., 2000 
Monocyte derived 
macrophages * 
CCR2-locus RFP Saederup et al., 2010 
T cells CD2-promoter GFP Singbartl et al., 2001 
*knock-in mouse strains 
 
Table 1 - Transgenic mouse lines widely used for in vivo imaging. 
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CHAPTER II - Aim of the study 
 
  
Though demyelination is an important feature in the pathogenesis of multiple sclerosis (MS), 
currently the mechanisms that mediate oligodendrocyte damage and myelin loss are not fully 
understood. The overall aim of my PhD work was to investigate how myelin is damaged in 
EAE, using a combined approach of in vivo imaging, confocal microscopy and ultrastructural 
analysis.   
The first project was focused on establishing a new strategy to reliably label myelin in vivo. 
This approach involved the local application of vital dyes that allowed us to visualize 
different cell types, subcellular compartments, organelles, and the release of soluble 
mediators.  A major advantage of this new method is that the use of vital dyes can be easily 
combined with transgenic labelling strategies (see Chapter I, Table 1), therefore enhancing 
the information gained in each experiment. It represents a reliable strategy to label cells and 
subcellular compartments, and provided that the right dyes are available can be a cheaper and 
faster alternative to the creation of new transgenic mouse lines. The aims of this project were 
to answer the following specific questions:  
 Which vital dyes can successfully be applied in vivo?  
 Which is the appropriate concentration and the application settings needed for an 
optimal imaging quality and tissue penetration? 
 What are the best fixation conditions that will allow further post-fixation analysis on 
the samples previously imaged with the vital dye?  
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With the first project I established a novel, fast and reliable way to label myelin in vivo. This 
finding was useful for the second project which centered on the in vivo analysis of the 
demyelination process. Oligodendrocytes and myelin are the main targets of the 
inflammatory attack in MS and its animal model EAE; however, the mechanisms underlying 
their damage could so far not be observed in vivo. Here I used advanced microscopy 
techniques to answer the following questions: 
 In the animal model EAE, how does demyelination occur?  What is the primary 
immune attack: oligodendrocytes or myelin? 
 Using in vivo imaging techniques, is it possible to detect changes in myelin structure 
and morphology which could be releated to demyelination? If yes, at which timepoint 
of the disease do they first appear and when are they most frequently encountered? 
 How do these morphological abnormalities appear at the ultrastructural level? 
 What are the molecular mechanisms that induce a change in the myelin structure and 
lead to demyelination in neuroinflammatory lesions? 
 What is the relevance of these findings for the human disease MS?  
 
The results of the first project have been published in a peer-reviewed journal (Romanelli et 
al., 2013), while a manuscript describing the results of the second project is currently in 
preparation.  
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CHAPTER III – Materials & Methods 
 
1. Materials  
 
Surgery procedures 
 
Surgery reagents  
Ketamine hydrochloride 10% (Ketamine) Bremer Pharma GmbH, Warburg, Germany 
Xylariem 20 mg (Xylazine) Riemser Arzneimittel AG, Greifswald-Insel 
Riems, Germany 
Forene (Isoflurane) Abbott AG, Baar, Switzerland 
Sterile artificial mouse cerebrospinal fluid 
(aCSF) 
Solution A: 
8,66 g NaCl (Merck) 
0,224 g KCl (Merck) 
0,206 g CaCl2 · 2H2O (Sigma-Aldrich) 
0,163 g MgCl2 · 6H2O (Sigma-Aldrich) 
 
Solution B:  
0,214 g Na2HPO4 · 7H2O (Merck) 
0,027 g NaH2PO4 · H2O (Merck) 
dH20 ad 500 ml  
 
Mixture of solutions A and B in a 1:1 ratio  
Bepanthen Augen- und Nasensalbe 5 g (eye 
cream) 
Bayer Vital GmbH, Leverkusen, Germany 
Ringerlösung Fresenius KabiPac 
(Ringer’s solution) 
Fresenius KaBI Dtl., Bad Homburg, 
Deutschland 
Cutasept F Lösung 250 ml 
(disinfectant spray) 
Bode Chemie GmbH & Co, Hamburg, 
Germany 
Agarose 
 
Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
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Surgical tools and materials  
Wella contura W7807 (Hair clipper) Wella, Darmstadt, Germany 
Syringe 3pc 5 ml OmnifixTM luer slip 
(syringe for injection of Ringer’s solution) 
B. Braun Melsungen AG, Melsungen, 
Germany  
BD Plastipak Hypodermic luer slip syringe 1 
ml (syringe for Ketamine/Xylazine and Ptx 
injection )  
Becton, Dickinson and Company, Franklin 
Lakes (New Jersey), USA  
 
Feather stainless steel blade (surgical 
blade)  
pfm medical ag, Cologne, Germany  
 
Noyes Spring Scissors (Large spring 
scissors)  
Fine Science Tools GmbH, Heidelberg, 
Germany  
Vannas-Tübingen Spring Scissors 
(Small angled spring scissors) 
Fine Science Tools GmbH, Heidelberg, 
Germany  
Dumont Mini Forceps – Inox Style 3 (Small 
forceps) 
Fine Science Tools GmbH, Heidelberg, 
Germany  
Dumont Mini Forceps – Inox Style 5 (Small 
forceps, smaller tip than Inox style 3) 
Fine Science Tools GmbH, Heidelberg, 
Germany  
Hypodermic Needles BD Microlance 3 30 
Gauge (0,3 mm, yellow) for subcutaneous 
injection of Ringer’s solution and anesthesia 
Becton, Dickinson and Company, Franklin 
Lakes 
(New Jersey), USA 
  
Ethicon Ethilon monofil 6-0 size, 
667H (skin suture) 
Johnson & Johnson Medical GmbH, 
Norderstedt, 
Germany 
Ethicon Vicryl 4-0 size, MIC101H 
(intracorporal suture) 
Johnson & Johnson Medical GmbH, 
Norderstedt, 
Germany 
Sugi (absorbent triangles)  Kettenbach GmbH & Co. KG, Eschenburg, 
Germany 
Metal plate Custom-made 
Cast Alnico Button Magnets Eclipse Magnetics Ltd, Sheffield, UK 
Rubber bands  
Support cushion Custom-made 
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Devices   
Olympus KL 1500 LCD (cold light source 
for stereomicroscopy) 
Olympus Deutschland GmbH, Hamburg, 
Germany 
Olympus Stereo Microscope SZ51 Olympus Deutschland GmbH, Hamburg, 
Germany 
FST 250 Hot Bead Sterilizer (sterilizer for 
surgical instruments) 
Fine Science Tools GmbH, Heidelberg, 
Germany 
T/Pump (Heating pad) Gaymar Industries, Orchard Park (New 
York), USA 
 
Perfusion and immunohistochemistry 
 
Reagents   
PFA (paraformaldehyde) 4% 8% PFA (Sigma-Aldrich) in dH2O, heated 
up to 55 °C and stirred additional 10 min, 
filtrated and mixed in a 1:1 ratio with 0.2 M 
PB (Phosphate buffer), pH adjusted to 7.2-
7.8 
Triton X-100 Sigma-Aldrich, Chemie GmbH, 82024 
Taufkirchen, Germany  
Sucrose Sigma-Aldrich, Chemie GmbH, 82024 
Taufkirchen, Germany 
PBS 10x (phosphate buffered saline),          
pH=7,2/7,4 
2,6 g NaH2PO4 · H2O 
14,4g Na2 HPO4· 2H2O 
87,5g NaCl (Merck) 
dH2O ad 1l 
TBS 10x (Tris buffered saline), pH=7,6 61 g Tris base (121,14 g/mol), (Sigma- 
Aldrich) 
90 g NaCl 
dH2O ad 1l 
O,2 M PB (phosphate buffer) 27,598 g NaH2PO4· H2O, 
35,598 g Na2 HPO4· 2H2O 
dH2O ad 1l 
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Gibco goat serum Invitrogen GmbH, Darmstadt, Germany 
DMSO Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
 
 
Antibodies, vital dyes and tracers  
Polyclonal rabbit anti-Iba1 Wako Chemicals GmbH, Neuss, Germany 
Monoclonal mouse anti-APC/CC1 Merck Millipore, Darmstadt, Germany 
Polyclonal rabbit anti-human MBP Dako/Agilent Technologies, Santa Clara 
(California), USA 
Goat-anti-rabbit Alexa fluor® 594 antibody Invitrogen GmbH, Darmstadt, Germany 
Goat-anti-mouse Alexa fluor® 635 antibody Invitrogen GmbH, Darmstadt, Germany 
Goat-anti-rabbit Alexa fluor® 488 antibody Invitrogen GmbH, Darmstadt, Germany 
DAPI Invitrogen GmbH, Darmstadt, Germany 
Isolectin GS-IB4 from Griffonia 
simplicifolia, Alexa Fluor 647 conjugate  
Invitrogen GmbH, Darmstadt, Germany 
Vybrant CFDA SE Cell Tracer Kit  Invitrogen GmbH, Darmstadt, Germany 
NeuroTrace 435/455 blue fluorescent Nissl 
stain  
Invitrogen GmbH, Darmstadt, Germany 
NeuroTrace 640/660 
deep-red fluorescent Nissl stain 
Invitrogen GmbH, Darmstadt, Germany 
Nuclear-ID Red DNA Stain  Enzo Life Sciences,  
ENZ-52406 
POPO-1 iodide (434/456)  Invitrogen GmbH, Darmstadt, Germany 
SYTO 64 red fluorescent nucleic acid stain  Invitrogen GmbH, Darmstadt, Germany 
Cell Trace BODIPY TR Methyl Ester Invitrogen GmbH, Darmstadt, Germany 
DiOC6(3)  
(3,3`-Dihexyloxacarbocyanine Iodide) 
Invitrogen GmbH, Darmstadt, Germany 
FluoroMyelin  red fluorescent myelin stain Invitrogen GmbH, Darmstadt, Germany 
FluoroMyelin green fluorescent myelin 
stain 
Invitrogen GmbH, Darmstadt, Germany 
MitoTracker Red CMXRos Invitrogen GmbH, Darmstadt, Germany 
Amplex UltraRed reagent  Invitrogen GmbH, Darmstadt, Germany 
Tetramethylrhodamine, methyl ester, Invitrogen GmbH, Darmstadt, Germany 
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perchlorate - TMRM  
Rabies virus SAD ΔG (CVS G) Provided by Karl-Klaus Conzelmann, Gene 
Center LMU, Munich 
 
 
Tools and materials for histology  
Microscope slides 76x26 mm Gerhard Menzel Glasbearbeitungswerk 
GmbH & Co. KG, Braunschweig, Germany 
Microscope cover slips 24x60 mm Gerhard Menzel Glasbearbeitungswerk 
GmbH & Co. KG, Braunschweig, Germany 
Parafilm Brand GmbH & Co. KG, Wertheim 
Germany 
Pipettes, pipette tips and tubes (2ml and 1,5 
ml) 
Eppendorf AG, Hamburg, Germany 
12-well cell culture plates Becton, Dickinson and Company, Franklin 
Lakes (New Jersey), USA 
Tissue Tek Cryomold Standard, 25x20x5 mm Sakura Finetek Europe B.V. , Alphen aan 
den Rijn, The Netherlands 
Tissue Tek Cryomold Biopsy, 10x10x5 mm Sakura Finetek Europe B.V. , Alphen aan 
den Rijn, The Netherlands 
Tissue Tek optimal cutting temperature 
(O.C.T.) 
Sakura Finetek Europe B.V. , Alphen aan 
den Rijn, The Netherlands 
Vectashield Mounting Medium Vector Laboratories, Inc., Burlingame 
(California), USA 
Paper filters (185 mm Ø circles) Whatman Schleicher & Schuell GmbH, 
Dassel, Germany 
50 ml centrifuge tubes Greiner Bio-One GmbH, Frickenhausen, 
Germany 
 
Technical devices  
Leica CM1850 cryostat Leica Microsystems GmbH, Wetzlar, 
Germany 
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Vibratome 1000Plus Intracel LTD, Shepreth, Royston, 
Great Britain 
Vortex-Genie 2 Scientific Industries, Inc., Bohemia (New 
York), USA 
KERN EW 150-3M (scales) Kern & Sohn GmbH, Balingen-Frommern, 
Germany 
Laboratory pH meter inoLAB WTW Wissenschaftlich-Technische 
Werkstätten, Weilheim, Germany 
Magnetic stirring hotplate MR 3001K and 
stirring bars 
Heidolph Instruments GmBH & Co. KG, 
Schwabach, Germany 
Ismatec IP high precision multichannel 
pump 
(pump for perfusions) 
ISMATEC SA, Labortechnik - Analytik, 
Glattbrugg, Switzerland 
Olympus IX71 inverted fluorescence 
microscope 
Olympus GmbH, Hamburg, Germany 
 
 
 Imaging 
 
Imaging devices  
FV1000 confocal system mounted on an 
upright BX61 microscope 
Olympus GmbH, Hamburg, Germany 
Olympus FV1000 MPE multiphoton 
Microscope, equipped with femtosecond-
pulsed Ti:Sapphire laser (Mai Tai HP, 
Newport/Spectra Physics) and opto-
electrical intensity regulation   
Olympus GmbH, Hamburg, Germany 
Objectives: x4/0.13, x10/0.4 air objectives; 
x25/1.05 water immersion objective; 
x40/0.85, x60/1.42 oil immersion objectives 
Olympus GmbH, Hamburg, Germany 
Small animal ventilator  Harvard Apparatus 
Intratracheal cannula (1.0 mm OD, 13 mm 
length) 
Harvard Apparatus 
Spinal clamping device (spinal adaptor for a 
stereotaxic frama) 
Narishige STS-A 
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Gravity superfusion system containing in-
line heater 
Warner Instruments 
vacuum system with suction tube Custom-built 
Stage for spinal clamping device Luigs & Neumann SM 5-9 stage and 
controller unit 
 
 
 EAE induction 
 
Reagents for immunization  
Purified recombinant MOG (from E. Coli) Stock solution, produced by laboratory of 
Doron Merkler (Universität Göttingen, 
University of Geneva)  
Purified MOG peptide (N35-55) Schafer-N Copenhagen, Denmark 
Mycobacterium Tuberculosis H37 RA Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
Incomplete Freund’s adjuvant (IFA) Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
Pertussis toxin from Bordetella pertussis, 
inactivated 
Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany 
  
 
Tools for immunization  
10 ml syringes Hamilton 
Hypodermic Needles BD Microlance 
3 23 Gauge (0,6 mm, blue) for subcutaneous 
emulsion immunization 
Becton, Dickinson and Company, Franklin 
Lakes 
(New Jersey), USA 
 
 
 
 
 
 Electron Microscopy 
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Reagents for tissue preparation  
Glutaraldheyde 50% Electron Microscopy Sciences,  
Hatfield, PA 19440, USA  
 
Formaldehyde 16% (PFA) Electron Microscopy Sciences,  
Hatfield, PA 19440, USA 
Sorensen’s Phosphate buffer 0.2M pH 7.2 
(PBS) 
Electron Microscopy Sciences,  
Hatfield, PA 19440, USA 
 
 
 Software 
 
Data analysis  
Adobe Creative Suite CS6 (Photoshop, 
Illustrator) 
Adobe Systems, Inc., San Jose, California, 
USA 
ImageJ General Public License 
http://rsbweb.nih.gov/ij/download.html 
Graphpad Prism GraphPad Software, La Jolla, California, 
USA 
Microsoft Office  (Powerpoint, Excel, Word) Microsoft Corporation, Redmond, 
Washington, USA 
Panoramic viewer 1.15 General Public License 
http://www.3dhistech.com/pannoramic_vie
wer 
Reconstruct General Public License  
http://synapses.clm.utexas.edu/tools/reconst
ruct/reconstruct.stm 
Imaris  Imaris® Analytical Image Processing 
Solutions for the Life Science, Bitplane 
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2. Methods 
 
Experimental animals 
 
All the animals were bred in our institute animal facility kept under controlled standard 
housing conditions. For the purpose of this study I have used several transgenic as well as 
wild-type mouse lines. In particular C57/Bl6 were ordered from Janvier Labs while 
BiozziABH mice were obtained from Harlan Laboratories, and consequently breed and 
crossed with different already established transgenic mice: Thy1-MitoCFP-P in which CFP 
expression is selectively directed to neuronal mitochondria (Misgeld et al., 2007b); Thy1-
XFP mice, with fluorescently labelled neurons (Feng et al., 2000); in CX3CR1
gfp/+ 
, GFP is 
expressed by resident microglia (Jung et al., 2000); in PLP-GFPm mice the PLP promoter 
localizes the GFP specifically to the oligodendrocyte lineage (Mallon et al., 2002); CCR2
rfp/+ 
show circulating monocytes labelled with RFP (Saederup et al., 2010); FcR quadruple 
knockout animals (kindly received from Dr. Verbeek at Leiden University Medical Center, 
The Netherlands). For the experiments only adult animals were used (between 6 and 12 
weeks of age) and both sex were equally distributed in controls and experimental groups. 
Animals were kept in Eurostandard Type II long cages 365x207x140 mmH (Tecniplast, 
Hohenpeißenberg, Germany) stored in IVC rack system with a maximum of five mice per 
cage. Autoclaved food (regular food “Maus” from Ssniff, Soest, Germany) and autoclaved 
tap water were supplied ad libitum. Mice were held at a 12 h light/12 h dark cycle. All animal 
experiments were performed in accordance with regulations of the animal welfare act and 
protocols approved by the Regierung von Oberbayern (permit numbers 55.2-1-54-2532-73-
13; 55.2-1-54-2532-25-08). 
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Induction of experimental autoimmune encephalomyelitis (EAE) 
 
Acute and chronic EAE were induced in adult animals (6-12 weeks) as previously reported 
(Abdul-Majid et al., 2000; Baker et al., 1990). The protocols were slightly different according 
to the mouse line and the experimental design. Briefly, mice with a Bl6 genetic background 
were injected with a total of 250 µl of an emulsion comprised of 200-300 µg of purified 
recombinant myelin oligodendrocyte glycoprotein (MOG, N1-125, expressed in E. Coli) in 
complete Freund’s adjuvant with 5 mg/ml mycobacterium tuberculosis H37 Ra. The mice 
received 200-400 ng of Pertussis Toxin at day 0 and day 2 after immunization. BiozziABH 
and BiozziABH/Bl6 animals were immunized following the protocol described previously 
(Baker et al., 1990), according to which the mice are injected with an emulsion containing 
purified recombinant MOG (50 µg) in complete Freund’s adjuvant at day 0 and day 7. On 
day 0, 1, 7, and 8 following immunizations, pertussis toxin (50 ng) was administered 
intraperitoneally.  
For the antibody transfer experiment, Thy1-YFP/Bl6 animals were immunized with MOG 
peptide (N35-55). They received a total of 200 µg of MOG emulsified with complete 
Freund’s adjuvant with 10 mg/ml mycobacterium tuberculosis H37 Ra. Pertussis toxin was 
injected at day 0 and day 2 after immunization at a concentration of 400 ng.  
Mice were weighed daily and the severity of the neurological deficits was expressed with a 
score: 0, no detectable clinical signs; 0,5, partial tail weakness; 1, tail paralysis; 1,5, gait 
instability or impaired righting ability; 2, hind limb paresis; 2,5, hind limb paresis with 
dragging of one foot; 3, total hind limb paralysis; 3,5, hind limb paralysis and fore limb 
paresis; 4, hind limb and fore limb paralysis; 5, death.  
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Immunohistochemistry 
 
Animals were lethally anesthetized with isofluorane and perfused transcardially with 20 ml of 
saline solution followed by 30 ml of 4% paraformaldeide (PFA) in 0.1 M phosphate buffer. 
Spinal cords were dissected out and post-fixed in 4% PFA overnight at 4°C. To cryoprotect 
the tissue, the tissue was transferred to 30% sucrose for at least 48hrs before embedding the 
specimens in Tissue-Tek optimal cutting temperature (O.C.T.) compound and freezing it at -
20°C. Subsequently I cut 20-30 µm longitudinal spinal cord sections and stained free-
floating. The sections were rinsed 3 times for 10 minutes in 1x PBS at room temperature and 
then incubated for 1 hr at room temperature with 10% goat serum. The following primary 
antibodies were applied and incubated overnight at 4°C in a solution containing 1% goat 
serum/0.1% NaN3/0.5% Triton/1x PBS: rabbit anti-Iba1 (1:200); mouse anti-APC/CC1 
(1:100); rabbit anti-MBP (1:200, cold methanol pre-treatment was necessary to obtain a sharp 
staining). The sections were later washed three times with PBS and incubated with a 
secondary antibody at 4°C in a solution containing 1% goat serum/0.1% NaN3/0.5% 
Triton/1x PBS: goat anti-rabbit Alexa 594 (1:1000), goat anti-mouse Alexa 633 (1:1000), 
goat anti-rabbit Alexa 488 (1:1000). All the samples were counterstained with Nissl-staining 
Neurotrace 640/660 (1:500) or DAPI (1:10000).  
After staining, the samples were mounted with Vectashield and covered with a coverslip 
glass sealed with nail polish. 
 
Confocal microscopy 
 
Fixed tissue samples previously stained were then scanned on a FV1000 confocal system 
mounted on an upright BX61 microscope (Olympus). The system was equipped with a 
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10x/0.4 water immersion objective, 20x/0.85 and 60x/1.42 oil immersion objectives, and with 
standard filter sets. Images were processed with ImageJ or AdobePhotoshop. 
 
 In vivo imaging 
 
Animals were first anesthetized with ketamine and xylazine (ketamine 87 mg/kg, xylazine 13 
mg/kg) and placed on a heating pad. To ensure a stable rate and minimize breathing artefacts, 
I performed a tracheotomy on the mice and attached them to a small ventilator. I then 
surgically exposed the dorsal spinal cord as previously described (Misgeld et al., 2007a; 
Nikic et al., 2011; Romanelli et al., 2013) removing 2-3 vertebrae; the opening was 
constantly superfused with artificial cerebrospinal fluid (aCSF). For the imaging session, the 
vertebral column was fixed using a spinal clamping device which allows a controlled 
movement of the mouse in x-y and z. I then created a well surrounding the spinal opening 
using 4% agarose: this helps to hold aCSF throughout the entire imaging sessions, as well as 
allows the incubation with vital dyes (Romanelli et al., 2013). In vivo imaging was performed 
using two-photon microscopes, either a custom-built setup based on Olympus FV300 or a 
commercially available Olympus FV1000 MPE. Both microscopes were equipped with 
femto-second pulsed Ti:Sapphire lasers, and the power was attenuated by a polarization-
based beam splitter or acoustic-optical modulators.  
For the imaging of vital dyes, Table 1 shows the optimal wavelengths necessary to obtain the 
best imaging quality in vivo.   
To study myelin alterations in vivo, I used Thy1-YFP16/Bl6xBiozziABH previously 
immunized; only mice with a score of ≥ 2.5 were used for the study. After bath application 
with MitoTracker Red at a concentration of 8 µM for 30 min, the spinal cord was carefully 
washed with aCSF before the imaging session. The laser was tuned at 910 nm in order to 
simultaneously excite both YFP (axons) and MitoTracker Red (myelin), and fluorescence 
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was collected using a green/red filter set (BA495-540, BA575-630). Imaging was focused 
within lesions, which were determined by the presence of morphologically altered axons; 
alternatively, I applied the nuclear dye POPO-1 Iodide (Romanelli et al., 2013) to visualize 
density of nuclei in order to define a lesion. To follow the change in myelin morphology over 
time, I aquired image stacks every 10 mins for several hours. The animal was kept 
anesthetized by injections of KX every 2 hours. Time-lapse images were acquired with a 
25x/1.25 water immersion objective at 1024 by 1024 pixel resolution, with a pixel dwell time 
of 2 µs/pixel.    
 The experiment was also performed in healthy animals to make sure that the morphological 
changes in myelin structures were not due to phototoxicity or dye toxicity; in control mice no 
signs of myelin alterations were detected even after several hours of imaging. 
 
Tissue fixation and processing for electron microscopy 
 
Thy1-YFP16/Bl6xBiozziABH animals with a score of ≥ 2.5 were transcardially perfused with 
2.5% electron microscopy grade glutaraldehyde (GA) and 2% PFA in 0.1 M phosphate buffer 
(pH 7.2). The spinal cords were microdissected and post-fixed in 2.5%GA/2%PFA overnight. 
The tissue was then embedded in 4% agarose and cut into thick sections (100-150 µm) using 
a vibratome. In order to visualize myelin and have a staining pattern comparable to the in 
vivo situation, I applied MitoTracker Red (8 µM for 5 hours at room temperature); after the 
incubation, the sections were carefully washed 3 times for 15 min in PBS and then mounted 
in PBS under a coverslip in imaging chambers built with parafilm spacers on a glass slide. 
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Near infrared branding (NIRB) and correlated serial electron microscopic 
reconstruction 
 
I imaged the samples on an Olympus FV100 MPE using confocal lasers 515 and 559 nm 
(ExDM405/488/559/635, BA505-540, BA575-620) in order to detect myelinosomes. Once 
the structure of interest was distinguished, NIRB marks were performed using the infra-red 
laser tuned at 910 nm, with a 640by640 pixel ratio and a pixel dwell time of 10 µs/pixel, 
using the water immersion 25x/1.05 objective. To subsequently locate the myelinosome with 
EM, I burned a big box of 100 µm x 100 µm around the structure, 2 µm superficial to the area 
of interest. 
Low- and high-resolution stacks were collected with the confocal microscope (Olympus 
FV1000) to document the structure of interest and the NIRB lines, using 4x/0.13, 20x/0.85 
and 60x/1.42 objectives.  
For the serial cutting, the sections were first transferred in Sylgard-line 35 mm Petri dishes. 
The samples were then bathed in diaminobenzidine in 0.1 M Tris buffer (pH 7.4) and the 
NIRB marks photo-oxidized by excitation with 520-560 nm. The photo-oxidized sections 
were then processed for EM and stained with 1% osmium tetroxide reduced in 1.5% 
potassium ferrocyanide, washed in 0.1 M sodium cacodylate buffer, and dehydrated in 
ascending ethanol series. After dehydration, tissue blocks were transferred in 100% 
propylene oxide and later embedded into embedding capsules and polimerized at 60°C for 48 
hrs.  Thick sections (0.5-1 µm) were cut with a glass knife; when the photo-oxidized NIRB 
marks became visible with the transmitted light and therefore the region of interest was 
identified, thin sections (50-70 nm) were serially cut (for detailed protocol see Bishop et al., 
2011). Sample processing for EM was performed by Prof. Dr. Derron Bishop (Indiana 
University School of Medicine, Muncie, USA). 
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Electron micrographs were obtained using at 120KV using a JEOL JEM-1400 equipped with 
a Gatan Ultrascan 1000XP camera. Images were then processed with the free software 
Reconstruct (http://synapses.clm.utexas.edu/tools/reconstruct/reconstruct.stm), while for the 
rendering it was used 3DMax.  
 
Histopathological analysis  
For the histopathological analysis I immunized and treated according to the specific 
experiment BiozziABH, BiozziABH/Bl6 and Thy1-YFP16/Bl6 mice, and perfused them with 
4% PFA. Prof. Dr. Doron Merkler (Univ. Geneva) and his team performed the stainings. 
Briefly: 3-4 µm thick sections were cut at the vibratome. Stainings were done on cross-
sections of lumbar, thoracic and cervical spinal cords. For the histopathological analysis of 
the inflammatory index, sections were treated with H&E staining and the total number of 
inflammatory foci was counted. To characterize the immune cells, macrophages were 
labelled with anti-Mac3 antibody, while for T cells it was used anti-CD3 antibody. For the 
demyelination analysis, the sections were stained with LFP/PAS; the area of demyelination 
was calculated as % of total white matter within a given section. To assess axonal pathology, 
sections were stained with Bielschowsky silver impregnation. Images were captured with a 
confocal laser scanning microscope (LSM510Meta) equipped with an upright Zeiss Axio 
Imager Z1 microscope; processing and quantification was performed using Panoramic 
Viewer 1.15 (http://www.3dhistech.com/pannoramic_viewer). 
For the human study, eight brain samples from biopsies of multiple sclerosis patients and 
three control cases without neurological diseases were provided by Prof. Dr. Wolfgang Brück 
(Univ. Goettingen). Brains were immediately fixed in PFA. For immunohistochemistry, 
biopsies were incubated with antibodies against myelin (anti-MBP), axons (anti-NF200), 
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oligodendrocytes (anti-NOGO-A), microglia/macrophages (anti-Iba1), and counterstained 
with the nuclear dye DAPI.  
 
Single cell labelling and quantification 
PLP-GFPm/Bl6xBiozziABH healthy and immunized animals were used to study 
oligodendrocyte morphology. At d7 post immunization, animals were first anesthetized with 
ketamine and xylazine (ketamine 87 mg/kg, xylazine 13 mg/kg); a laminectomy was then 
performed at the level of the lumbar spinal cord (Romanelli et al., 2013; Misgeld et al., 
2007b; Nikic et al., 2011). Rabies Virus SAD ΔG mCherry was injected undiluted in the 
white matter of the lumbar spinal cord with a glass capillary. Specifically, I injected 0.5 µl of 
virus at a depth of 0.2-0.4 mm into the white matter. Each mouse received two infusions. 
Temgesic was administered intraperitoneally before the surgery and for two consecutive 
days. All the animals were weighed and scored daily and sacrificed 9 days after Rabies Virus 
injections. 
Quantification of the number and length of singe oligodendrocytes as well as the 3D 
rendering, were obtained using the software Imaris Scientific 3D/4D Image processing. In 
details: the total number of the primary processes exiting the cell soma (not the secondary 
branches) were counted and expressed as the average number of processes per OL; the length 
of all the processes (primary and branches) was traced and measured in mm.     
 
Antibody transfer experiment 
To assess the role of antibodies during demyelination, I injected the anti-MOG monoclonal 
antiboby 8.18C5 (2.8 µg/µl produced and kindly provided by Dr. Krishnamoorthy, Max-
Planck Institute of Neurobiology). The animals were subdivided into two groups: the 
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experimental group received 250 µg of antibody intraperitoneally for three days, at weight 
loss, one and two days after onset of clinical symptoms (Urich et al., 2006; Pöllinger et al., 
2009); the control group was injected intraperitoneally at the same time points with 10 µg of 
IgG1 Isotype control.  
The mice were weighed and scored daily for EAE severity and were sacrificed three days 
after onset of clinical signs.  
 
B cells depletion protocol 
C57Bl6 and BiozziABH/Bl6 mice were treated with anti-hCD20 antibody. To ensure 
efficient B-cell depletion, the animals were injected weekly (for three consecutive weeks) 
with 200 µg of anti-hCD20 monoclonal antibody (at a stock concentration of 28.98 µg/µl), 
prior to immunization with recombinant MOG protein. The control group received instead 
200 µg of antiragweed immunoglobulin IgG2a-isotype control monoclonal antibody (at a 
stock concentration of 5.6 µg/µl). Both anti-CD20 and isotype control were kindly provided 
by Prof. Dr. Martin Weber (Univ. Goettingen). 
Serum was collected in order to check the antibody titers and ELISA assay was performed by 
Prof. Dr.  Martin Weber and his group. 
 
Fixed tissue quantification 
Sequence of myelin loss: PLP-GFPm/Bl6xBiozziABH mice were immunized and perfused 
with 4% PFA two days after onset. The sections were then cut longitudinally and stained free 
floating for anti-MBP as described earlier. For each animal, three areas respectively 
comprised of three lesion centers, three lesion borders and three normal appearing white 
matter regions, were selected to count.  ImageJ was used for the processing and quantification 
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of the areas. Specifically, the “cell counter” plugin was used to count the number of 
oligodendrocytes and the number of nuclei. The length of myelin was traced using the 
“freehand line” tracing tool and the “measure” plugin, and expressed in mm.  
 
Myelinosome quantification: Myelinosomes analysis both in Thy-YFP16/bl6xBiozziABH 
and in Thy1-YFP16/bl6 treated with 8.18C5, were performed in the same way. Sections were 
stained with anti-MBP and a nuclear dye to visualize the lesion areas. High magnification 
images were taken with confocal lasers using 60x/1.42 oil objective at a zoom of 4 fold at the 
border of the lesions. Quantification was performed using ImageJ and its “trace and measure” 
plugins: the length of each axon was measured and the frequency of myelinosomes 
appearance (detected with the MBP signal) was expressed as density of myelinosomes per 
mm of axon. 
 
Quantification of human brain samples: For the analysis of the human samples, images were 
opened with the software Panoramic Viewer and consequently exported as .tif files in 
ImageJ. To count the number of DAPI+ cells and the number of oligodendrocytes, I used the 
“cell counter” plugin. Length of myelin was measured with the “trace and measure” plugins, 
as described before.  
Myelinosome quantification was performed in the same way as described for the murine 
model.  
 
Statistics 
Results are expressed as mean ± SEM, unless indicated otherwise.  
Data set were tested for normal distribution with the D’Agostino-Pearson normality test using 
GraphPad Prism Software. When normal distribution could be assumed the data were 
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compared using student t-test or, if there were more than two samples, analysed using 
ANOVA followed by Bonferroni’s multiple comparison tests. When normal distribution 
could not be assumed, the nonparametric Mann-Whitney test, or if there were more than two 
samples, the Kruskal-Wallis followed by Dunn’s multiple comparison tests were chosen. 
Statistical analyses were performed with GraphPad Prism software.  
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CHAPTER IV – Results 
 
1. In vivo imaging of the spinal cord using vital dyes 
 
Over the past decades, there has been a growing interest in the use of in vivo imaging 
techniques at least partly due to the development of new transgenic mouse lines that express 
genetically encoded fluorescent proteins or sensors (see Chapter I, section 3).  However, the 
generation of new transgenic lines requires a lot of time and resources, and when the labeling 
needs to be combined or used in disease models, complex breeding strategies are necessary. 
In this scenario, synthetic dyes represent a good alternative or complement: they can be easily 
combined with transgenic labeling and are available in variants that cover a broad range of 
the wavelength spectrum. The majority of these dyes has already been tested and so far 
mainly used in in vitro studies, with few exceptions used in vivo, such as sulforhodamine 101 
(Nimmerjahn et al., 2004; Nimmerjahn et al., 2009) or calcium indicator dyes (Stosiek et al., 
2003; Johannssen et al., 2010; Grienberger et al., 2012). In my first project I have tested 
several vital dyes and evaluated their potential for in vivo labeling. During this process I have 
also established a novel technique to label myelin, which allowed me to follow demyelination 
in vivo in my second project.  
 
Surgical procedure and imaging setup 
 
In vivo imaging requires surgical exposure of the spinal cord. To access the dorsal spinal 
cord, I performed a laminectomy using spring scissors, as described in previous reports 
(Misgeld et al., 2007a; Davalos et al., 2008; Davalos et al., 2012). Once the region of 
interest is accessible, the animal must be stabilized under the microscope in order to allow a 
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controlled movement of the tissue in x-y and z. This is achieved by use of a spinal clamping 
device to fix the position of the spinal cord, thus minimizing movements and breathing 
artifacts (Fig. 8 a-b).  
 
Figure 8 - Experimental setup.  (a) Imaging setup of FV1000MPE including custom-built stage to 
hold spinal stabilization device. (b) Side view of the mouse held by the spinal stabilization device to 
show the position of the 25x/1.05NA objective between the clamps and within the liquid filling the 
agarose well. (c) View from above of exposed lumbar spinal cord that has been clamped (1) and 
agarose well has been built surrounding the cord to allow for dye application without leakage (2). 
 
To improve the imaging quality and, as I will explain in the next section, to obtain a deeper 
penetration of the vital dye, the meninges (dura mater and arachnoidea) must be carefully 
removed using a needle and fine forceps. The intact meninges in fact represent an obstacle for 
the labeling with vital dyes, which would only stain the structures within the dura mater and 
the arachnoidea and not the spinal tissue beneath (Fig. 9).   
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It is also important to keep the laminectomy opening covered with artificial cerebrospinal 
fluid, both to avoid damage of the exposed spinal cord and for an optimal dye exposure. 
Thus, before the imaging session begins, an agarose well can be formed around the spinal 
opening, taking extra care to avoid any leakage (Fig. 8c).  
Figure 9 - Removal of the meninges. (a)  After laminectomy, the meninges are first punctured with 
the tip of a hypodermic needle to allow access with surgical tools.  The reflective surface, labeled by 
an asterisk, is indicative of an intact dura and is absent in the right panel where the meninges (dura 
and arachnoidea) have been peeled off using fine forceps.  The direction in which the meninges have 
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been pulled is indicated by the arrow. The free margin of the meninges is outlined by a dotted 
line. Removal of the meninges substantially improves the quality of labelling, e.g. by MitoTracker 
Red (b, magenta images equalized to full dynamic range so note higher noise level in left panel), as 
well as nuclear labelling with POPO-1 iodide (cyan), which will stain primarily cells in the meningeal 
layers if the meninges are left on (c), as opposed to when the meninges are removed (right panel). X-
z projection of an image stack with (left) or without (right) the dura and arachnoidea in place (d) 
shows that penetration into spinal cord is doubled when the dura is removed; (1) dorsal spinal cord; 
(2) subarachnoideal space; (3) dura mater and arachnoidea. Scale bar in a, 1 mm; scale bar in b, 10 
µm; scale bar in c, 50 µm; scale bar in c inset, 10 µm. Images taken from Romanelli et al., 2013.  
 
 
Concentration dependence and reliability of vital dyes 
 
Together with Dr. Catherine Sorbara and Dr. Ivana Nikic, we have tested a range of 
commercially available vital dyes and identified the optimal application and imaging 
conditions (Table 2: in bold font the best suited for in vivo imaging, based on reliability, 
brightness, longevity during imaging and ability to be fixed). The vital dyes have been 
classified in structural (cell-type specific or targeted to a specific subcellular compartment), 
and functional. 
Finding the appropriate concentration is particularly important, as some of the dyes might 
label different structures depending on their dilution. For example, as shown in Fig. 10, 
MitoTracker Red labels mitochondria when used at low concentration (Fig. 10 a); a moderate 
increase labels both mitochondria and myelin (Fig. 10 b), while if used at high concentration 
it labels exclusively myelin (Fig. 10 c).  
For each dye, I have studied the penetration and the labeling efficiency. Most of the dyes 
penetrate up to 30 µm into the spinal cord (the depth that can be imaged in the heavily 
myelinated spinal cord is around 40 µm, therefore more limited than in the cortex) (Table 2). 
Direct comparison of these dyes with established transgenic or immunohistochemical 
markers has allowed me to determine the labeling efficiency, which is nearly 100% for the 
nuclear dyes, as well as for myelin (MitoTracker Red) and for activated 
macrophages/microglia (Isolectin B4), while it is at least 40% for the rest of the dyes.  
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Figure 10 - Concentration dependence. The vital dye MitoTracker Red can be used to label different 
structures depending on the concentration: (a) sparse mitochondrial labelling is achieved following 
application of 0.5 µM MitoTracker Red (magenta), which co-localizes with genetically labelled 
mitochondria in MitoMice (described in Misgeld et al., 2007b) (merge); (b) increase of the dye 
concentration to 2 µM reveals myelin, while only few mitochondria remain visible (arrowhead); (c) 
after further increase of the dye concentration to 8 µM only myelin is visible, likely because the 
intensity of myelin labelling increases compared to the mitochondrial labeling. Scale bar in a, 5 µm; 
scale bar in b, 5 µm; scale bar in c, 5 µm. Image taken from Romanelli et al., 2013. 
 
Another feature of the vital dyes is their extreme reliability when re-applied over time. To 
evaluate this aspect, Dr. Catherine Sorbara has applied two spectral versions of a nuclear dye 
at different timepoints (NeuroTrace 435/455 at 0h and NeuroTrace 640/660 at 1h). The 
comparison of the obtained staining patterns revealed nearly identical labeling structures, 
with 94 ± 5% of NeuroTrace 435/455+ nuclei subsequently relabeled with NeuroTrace 
640/660 (Fig. 11 a). A similar result was obtained with the re-application of the same dye 
(carboxyfluorescein -CFDA-) after photobleaching (97 ± 2% of bleached cells were relabeled 
with CFDA) (Fig. 11 b). These results show that the same cells can be reliably relabeled and 
followed over extended periods of time thus facilitating long imaging sessions and detection 
of changes in the cellular or subcellular composition. 
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Figure 11 - Reliability of relabeling.  Consecutive labeling of the same dorsal spinal cord at two time 
points (0 and 1 hr) with two spectrally distinct versions of a nuclear dye, Neurotrace (NT) 435/455 
(a, left) and NT 640/660 (a, middle) reveal a near exact labeling pattern (a, right, merge).  Vybrant 
CFDA was applied to a healthy spinal cord (b, left) and bleached with a two-photon 
laser (b, middle).  Following reapplication of the vital dye, the same cells were labelled 
(b, right).  Scale bar in a, 50 µm; scale bar in b, 10 µm. Image taken from Romanelli et al., 2013. 
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Dye   Company, 
Order No. 
Labeled 
structure 
Dilution/ 
Concentration 
Incubati
on time  
Optimal 
Excitation  
(nm) 
Persistence 
of label 
Penetration 
Depth, 
Comparison 
to Genetic 
label 1 
Labeling 
Efficiency2 
Fixation 
(in 4% 
PFA) 
Structural Dyes        
Cell- type specific dyes        
Isolectin GS-
IB4 from 
Griffonia 
simplicifolia, 
Alexa Fluor 
647 
conjugate  
Invitrogen
I32450 
activated 
microglial 
cells 
(macropha
ges) 
200 μM 1 hr 840 (2P) > 2hr 14 ± 2 m,  
35 ± 2 % 
87 ± 5% 
3
  yes 
Vybrant 
CFDA SE 
Cell Tracer 
Kit  
Invitrogen
V12883 
OLs 25 μM 30 min  800 (2P) > 2hr 18 ± 4 m,  
45 ± 4 % 
54 ± 7%
4
 Yes 
 
Subcellular compartment 
dyes 
        
NeuroTrace 
435/455 blue 
fluorescent 
Nissl stain  
Invitrogen 
N-21479 
Nuclei 1:250 30 min 850 (2P) > 2hr   yes 
NeuroTrace 
640/660 
deep-red 
fluorescent 
Nissl stain 
Invitrogen
N-21483 
Nuclei 1:250 30 min 740 (2P) > 2hr   yes 
Nuclear-ID 
Red DNA 
Stain  
Enzo Life 
Sciences  
ENZ-
52406 
Nuclei 1:250 45 min 740 (2P) > 2hr 20 ± 1 m,  
50 ± 1% 
96 ± 4% 
5
  yes  
 
POPO-1 
iodide 
(434/456)  
Invitrogen
P3580 
Nuclei 1 μM 30 min 850 (2P) > 2hr 16 ± 3 m,  
40 ± 3% 
100% 
6
 yes 
SYTO 64 red 
fluorescent 
nucleic acid 
stain  
Invitrogen
S11346 
nuclei 2.5 μM 45 min 700 (2P) > 2hr   yes 
Cell Trace 
BODIPY TR 
Methyl Ester 
Invitrogen
C34556 
myelin 100 μM 40 min 780 (2P) re-apply 
after 2hr 
  yes, but 
weak 
signal 
DiOC6(3)  
(3,3`-
Dihexyloxaca
rbocyanine 
Iodide) 
Invitrogen 
D273 
myelin 5 μM 45 min 910 (2P) > 2hr   yes, but 
weak 
signal 
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1
Percentage based on comparison to the imaging depth of transgenic mouse line, thy1-YFP
16
MitoP.  
2
Labeling efficiency calculated as percentage of a well-established immunohistochemical or 
transgenic marker double-labeled with a given vital dye (n=3 animals per dye, see methods for 
labeling procedure). 
3
 Percentage of Anti-Iba1 (rabbit antibody, WAKO) positive cells double-positive for Isolectin. 
4
 Percentage of Anti-APC (mouse monoclonal antibody clone CC-1, Calbiochem) positive cells. 
double-positive for CFDA. 
5
 Percentage of DAPI (4', 6-diamidino-2-phenylindole, Invitrogen) positive cells double-positive for 
Nuclear ID. 
6
 Percentage of NT 530/615 (Neurotrace red fluorescent nissl stain, Invitrogen) positive cells double-
positive for POPO-1 iodide. 
7 
Percentage of mitochondria in a thy1-MitoS, double-positive for MitoTrackerRed. 
 
Table 2 - Vital dyes for cellular, subcellular and functional imaging. Table taken from Romanelli et 
al., 2013.  
 
 
FluoroMyelin  
red 
fluorescent 
myelin stain 
Invitrogen
F34652 
myelin 1:50 30 min 940 (2P) > 2hr   yes, but 
weak 
signal 
FluoroMyelin 
green 
fluorescent 
myelin stain 
Invitrogen
F34651 
myelin 1:50 30 min 910 (2P) > 2hr   yes, but 
weak 
signal 
MitoTracker 
Red 
CMXRos 
Invitrogen
M7512 
myelin 
and 
mitochond
ria 
0.5 μM 30 min 740 (2P) > 2hr 14 ± 1 m,  
35 ± 1% 
43 ± 6% 
7
 no 
MitoTracker 
Red 
CMXRos 
Invitrogen
M7512 
myelin 8 μM 30 min 740 (2P) > 2hr 18 ± 2 m,  
45 ± 2% 
95 ± 2% 
8
 no 
Functional 
Dyes 
         
Amplex 
UltraRed 
reagent  
Invitrogen
A36006  
hydrogen 
peroxide 
sensor 
(extracellu
lar) 
200 μM 30 min  RFP 
excitation 
(1P)  
740 (2P) 
~20min 31 ± 4 m,  
78 ± 4 % 
 n/a 
Tetramethyl
rhodamine, 
methyl ester, 
perchlorate - 
TMRM  
Invitrogen           
T-668 
mitochond
rial 
potential 
0.6 μM 30 min 910 (2P) > 2hr 20 ± 2 m,  
50 ± 2% 
60. ± 10% 
9
  
n/a 
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Structural dyes 
 
As shown in Table 2, the vital dyes have been categorized in structural and functional dyes. 
Among the structural ones, some show high cell-type specificity. For example, it appears that 
Vybrant CFDA SE Cell Tracer labels preferentially oligodendrocytes. I have applied CFDA 
on the spinal cord of Plp-CreERT2xTdTomato mice, in which the Plp promoter drives the 
expression of the fluorescent protein selectively to oligodendrocytes (Leone et al., 2003): the 
vital dye colocalizes with transgenic somata and processes (Fig. 12 a). An advantage of this 
dye is that it can be fixed after the imaging session, allowing further analysis to be performed. 
To assess the specificity of the dye, I stained the tissue with the oligodendrocyte marker 
APC-CC1 (Fancy et al., 2010) which showed that about half of the APC-CC1+ 
oligodendrocytes were also CFDA+; in the same analysis, only a small portion of astrocytes 
(stained with the marker S100) and microglia cells (identified by Iba1 staining) were labeled 
with CFDA (Fig. 12 b, c).  
Another example of a dye that results in cell-type specific labeling is Isolectin GSA-B4. 
Previous studies have shown that it can be successfully used to label microglia in fixed tissue 
and living slices (Moreira et al., 2009; Dailey et al., 1999). I tested its use in vivo in a mouse 
in which I previously induced EAE. Fig. 12 d shows a lesion with a high density of activated 
macrophages/microglia; after fixation with paraformaldehyde, the co-staining with a 
macrophages/microglia marker (Iba1) showed that more than 80% of the cells were double 
positive for Isolectin GSA-B4 (Fig. 12 f). The application of Isolectin GSA-B4 in a 
CX3CR1
GFP/+ 
transgenic mouse in which resident macrophages/microglia are labeled with 
GFP (Jung et al., 2000) show co-labeling of the same cells after EAE induction. The same 
vital dye seems not to stain resting microglial cells (Fig. 12 e). 
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Figure 12 - Cell-type specific dyes. (a) The dye CFDA (green) co-localizes with somata and 
processes of transgenically labeled oligodendrocytes in a tamoxifen-injected Plp-CreERT2 x 
TdTomato mouse. (b) Post-imaging fixation of CFDA (green) stained with an anti-APC (CC-1) 
antibody (red) to label mature oligodendrocytes. (c) Low magnification of a spinal cord stained with 
CFDA (green) and the nuclear dye Neurotrace 435 (red). Some nuclei are CFDA positive 
(arrowheads) while others are not co-labeled (arrows). (d) Activated microglia/macrophages stained 
with Isolectin GSA-B4 (red) and counterstained with the nuclear dye, POPO-1 iodide (cyan), in a 
C57BL/6 mouse, 2 days after onset of EAE. (e) In vivo labelling of Isolectin GSA-B4 (red) in a 
CX3CR1 transgenic mouse. (f) Isolectin GSA-B4 was applied in vivo and consecutively fixed (red); 
the tissue was then counterstained with an anti-Iba1 antibody (cyan) to label activated and resting 
microglia. Scale bar in a, 10 µm; scale bar in b, 10 µm; scale bar in c, 20 µm; scale bar in d, 50 µm; 
scale bar in e, 20 µm; scale bar in f, 25 µm. Image taken from Romanelli et al., 2013. 
 
Some vital dyes stain specific subcellular compartments. Nuclei for example can be easily 
labeled with a wide range of dyes, using relatively low concentration and short incubation 
time. Their labeling efficiency is nearly 100% when comparing the in vivo labeling with 
postmortem staining using the nuclear dye DAPI (Fig. 13 a). The most reliable results were 
obtained with POPO-1 Iodide and Nuclear ID Red, both are easy to apply and extremely 
reliable.  
For my work, it was also essential to find a suitable dye for labelling myelin. In my hands, 
MitoTracker Red gave the best results. As shown in Fig. 13 b, MitoTracker Red gives a 
bright and clear myelin labeling, and also clearly depicting nodes of Ranvier; notably, the dye 
labels the outermost layers of myelin, as shown by the gap between the myelin stain and the 
cytoplasmic labeling of the axon. Another dye commonly used in vitro is Fluoromyelin 
(Watkins et al., 2008; Monsma et al., 2012). Its application in vivo appears to be a good 
alternative to MitoTracker Red (Fig. 13 c); the labeling pattern of the two dyes is in fact very 
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comparable, though Fluoromyelin requires a higher concentration. One advantage of 
Fluoromyelin over MitoTracker Red is its fixability allowing further studies after the imaging 
session. As myelin dyes are very sensitive, a general rule is to pay extra attention to the 
removal of blood clots and meninges in order to ensure a good penetration of the dye.  
Figure 13 - Dyes specific for subcellular compartments. (a) Overview of a healthy spinal cord in vivo, 
where NuclearID Red is used to visualize nuclei (red). The same spinal cord was fixed post-imaging 
and imaged by confocal microscopy to reveal nearly identical staining (arrows identify examples of 
identical cells in vivo and post mortem; arrowheads indicate differences in the labelling pattern, 
probably due to minor changes in the way the spinal cord is angled). Counter-stain with DAPI (cyan) 
post mortem confirms specific nuclear localization of the in vivo NuclearID label (merge). (b) High 
magnification view of a healthy axon and its myelin, labeled with MitoTracker Red (magenta). (c) In 
vivo co-labeling of myelin with MitoTracker Red (magenta) and Fluoromyelin (green). The arrow 
identifies a node of Ranvier. Scale bar in a, 50 µm; scale bar in b, 10 µm; scale bar in c, 10 µm. 
Image modified from Romanelli et al., 2013. 
 
 
Functional dyes 
 
Dr. Ivana Nikic and Dr. Catherine Sorbara have tested some vital dyes to detect the release of 
toxic mediators. Amplex UltraRed, for example, detects extracellular hydrogen peroxide. 
Nikic et al. have usued it in their study, and they showed that Amplex signal is increased in 
acute inflammatory lesions of EAE animals (Nikic et al., 2011) (Fig. 14 a).  
A different functional dye can be used to assess mitochondria function. 
Tetramethylrhodamine (TMRM) works nicely in vivo and can be used to study mitochondrial 
potential in axons. The penetration of TMRM is however limited and only a subset of axonal 
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mitochondria is labelled by this dye when compared with the fluorescent pattern observed in 
transgenic MitoMice (Misgeld et al., 2007b). Interestingly, the application of cyanide m-
chlorophenyl hydrazone (CCCP), a protonophore, immedinately release TMRM from 
mitochondria (Fig. 14 b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 - Functional dyes. Measurement of extracellular H2O2 concentration detected with Amplex 
UltraRed (a, red) in the dorsal spinal cord of healthy (a, left), EAE untreated (a, middle; 2 days after 
onset) and EAE mouse treated intraperitoneally with a cocktail of reactive oxygen species (ROS) 
scavengers beginning at weight loss (a, right; 2 days after onset). Mitochondrial potential was 
assessed by bath application of TMRM (b, red). Mitochondrial labelling disappears immediately after 
application of 100 µM CCCP (right). Scale bar in a, 250 µm (calibration bar); b, 50 µm. Image taken 
from Romanelli et al., 2013. 
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Use of vital dyes to assess disease models in the spinal cord 
 
I screened a number of vital dyes in order to find the most suitable candidates to use in vivo, 
because the final aim of this project was to combine the use of these dyes with transgenic 
mouse strains. This approach increases the number of questions that can be addressed in a 
single in vivo experiment and represents a relatively easy way to avoid the generation of new 
transgenic lines or crosses.  
Figure 15 - Anticipated results. (a) Overview of the spinal cord of a healthy Thy1-YFP
16
 mouse, 
where Mitotracker Red (magenta) and POPO-1 iodide (cyan) have been applied to stain myelin and 
nuclei, respectively. Nuclei, myelin and axons appear normal. (b) Overview of a Thy1-YFP
16 
mouse 
labelled with the same dye combination at 2 days after onset of EAE. Here, infiltrating nuclei, myelin 
and axonal damage are indicative of an inflammatory lesion. Note that some inflammatory cells also 
label with the MitoTracker Red dye. Higher magnification views shown on the right. Scale bar 
in a, b, overview, 50 µm; scale bar insets, 10 µm. Image taken from Romanelli et al., 2013. 
 
This method is versatile and can be applied to different disease models. In the work described 
here I have used several transgenic mouse lines in combination with myelin and nuclear dyes, 
in the EAE model for MS. Fig. 15 shows a Thy1-YFP transgenic mouse in which I have 
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labeled myelin with MitoTracker Red and nuclei with POPO-1 iodide: in the control mouse, 
axons and myelin appear healthy and only few cells are present in the imaging area; in the 
EAE animal instead axons and myelin are damaged which results in some of the axons 
showing swellings and beading, and myelin debris becoming apparent in the lesion area. The 
high density of nuclei is also indicative of an inflammatory lesion.  
 
2. In vivo analysis of myelin in multiple sclerosis and its animal model 
 
Although demyelination represents the major histopathological hallmark of MS, currently 
very little is known about the mechanisms that mediate myelin damage. My second project 
aimed at understanding how myelin is damaged in EAE, by combining two-photon in vivo 
imaging with confocal microscopy and correlated ultrastructural analysis. 
 
Characterization of the animal model 
As reviewed in section Chapter I - section 1, several animal models are available to study 
inflammation and demyelination in the CNS. For my experiments, I have induced EAE 
induced in Biozzi ABH mice crossed with different transgenic reporter lines. The Biozzi 
ABH strain develops relapsing-remitting EAE which in later stages results in a steady 
progression of the disease, and therefore represents a good model for the study of both 
relapsing-remitting as well as secondary progressive MS. Conversely to the commonly used 
C57/Bl6 animals, Biozzi ABH mice manifest a strong antibody response and extensive 
demyelination indicating that they are well suited to investigate myelin damage. 
In order to visualize neurons and their axons, or oligodendrocytes, it was necessary to breed 
Biozzi ABH mice with already described Bl6 transgenic lines. To assess whether the 
interstrain crossing (Biozzi ABH/Bl6) affects disease presentation in the F1 hybrids 
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compared to the pure line (Biozzi ABH), I have performed histopathological analysis to 
assess the extent of the demyelinated area, axonal survival and the number of inflammatory 
loci.  
First, the mice were immunized with 50 µg of recombinant MOG protein at day 0 and day 7, 
and pertussis toxin (50 ng) was injected at day 0, 1, 7 and 8. Ten to twelve days after the 
induction of EAE, the mice showed the first clinical symptoms. The peculiar clinical course 
of the disease which characterizes Biozzi ABH strain was reflected also in Biozzi ABH/Bl6 
(F1 generation): the first 20 to 30 days are characterized by an alternation of relapses and 
periods of remission, with the first relapse being considered as the acute timepoint of the 
disease. Following the initial relapsing-remitting phase, the pathology progresses steadily in 
the chronic phase (Fig. 16). 
Figure 16 - Clinical course of EAE in BiozziABH (a) and BiozziABH/Bl6 (b). The disease 
progression is nearly identical, and characterized by a relapsing-remitting period where the first 
relapse represents the acute phase, and a chronic progression of the symptoms (BiozziABH, n=5 
mice; Biozzi/Bl6, n=5 mice). 
 
The mice were then analyzed for inflammation, demyelination and axon density. 
Histopathological staining was performed on PFA-fixed cross-section of lumbar, thoracic and 
cervical spinal cord. The number of inflammatory lesions per spinal cord cross-section was 
quantified by H&E staining and expressed as inflammatory index.  Demyelination was 
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quantified by measuring the demyelinated area on LFB/PAS stained sections and expressed 
as % of total analyzed area of white matter within a given section. Bielschowsky silver 
impregnation was used to assess the axonal density. I performed the study both at the acute 
and at the chronic timepoints. As shown in Fig. 17 and Fig. 18, there is no significant 
difference in the pathology of the EAE disease between pure Biozzi ABH and F1 generation 
Biozzi ABH x C57/BL6 mice. Furthermore the area of demyelination continues to increase 
between the acute and the chronic timepoint suggesting an ongoing demyelination process.  
Taken together these results confirm that the chosen model is suitable for our study of 
inflammatory demyelination, and that the breeding with a transgenic Bl6 mouse line does not 
affect the typical Biozzi ABH disease pathology.  
The histopathological stainings were kindly performed by Prof. Dr. Doron Merkler (Univ. 
Geneve). 
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Figure 17 - Histopathological analysis at the acute timepoint. Here is shown the same cross-section 
from the lumbar spinal cord of a Biozzi/Bl6 animal.  (a) The inflammatory index is expressed by the 
number of inflammatory loci within a cross-section, identified by H&E staining. (b) LFB/PAS 
staining is used to determine the demyelinated area, expressed as a % total analyzed area of white 
matter in the given section. (c) The axon density shows the % of surviving axons, quantified with 
Bielschowsky silver impregnation. (BiozziABH, n=5 mice; Biozzi/Bl6, n=5 mice). Scale bars in (a) 
200 µm (overview) and 50 µm (inset). 
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Figure 18 - Histopathological analysis at the chronic timepoint. Here is shown the same cross-section 
from the lumbar spinal cord of a Biozzi/Bl6 animal.  The inflammatory index (a), the demyelinated 
area (b), and the axon density (c), are analyzed as described before. (BiozziABH, n=5 mice; 
Biozzi/Bl6, n=5 mice). Scale bars in (a) 200 µm (overview) and 50 µm (inset). 
 
 
Cellular sequence of demyelination in acute EAE 
 
As outlined in the introduction section it is well established that MS lesions are characterized 
by oligodendrocyte pathology and myelin loss (see Chapter I – Pathology of MS), yet it is 
currently still debated where oligodendrocyte damage starts and whether oligodendrocyte 
pathology thus follows an “outside-inside” or “inside-outside” gradient.   
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I first tried to address this question in our EAE model. To characterize the lesions observed in 
this model, PLP-GFPm/Bl6 x BiozziABH mice were bred in our animal facility; in these 
mice, the PLP promoter drives the expression of green fluorescence protein (GFP), allowing 
to visualize OLs cell bodies and their processes. After immunization with MOG, I quantified 
the density of OLs and the length of myelin within a given lesion and its surroundings. The 
lesion area was determined by the number of infiltrating cells, with the lesion center 
characterized by a high density of cells, decreasing towards the rim (Fig. 19 a-b).  
The results observed in BiozziABH/Bl6 mice seem to indicate an outside-inside gradient of 
oligodendrocyte damage: while myelin is lost not only at the center of the lesion but also at 
its border, OL cell loss is significant only in the lesion center while their density is nearly 
identical to the healthy animals at the rim of the lesion (Fig. 19 c).  
 
Figure 19 - Sequence of demyelination. Overview of a PLP-GFPm X BiozziABH mouse spinal cord 
in a healthy control (a) and EAE (b), stained with the nuclear dye Neurotrace (cyan) and MBP 
(magenta), while oligodendrocytes are transgenically GFP positive (green). In healthy example, the 
cells look organized and myelin intact; on the contrary, in the EAE animal it is visible a clear lesion 
with a high density of infiltrating cells, and where myelin appears damaged and debris are scattered 
within the lesion. (c) Quantification of the OLs number and myelin length performed at the peak of 
the disease (2 days after the appearance of the first symptoms, On+2) at the center of the lesion (high 
infiltration), at the border (medium infiltration) and far from the lesion site (low infiltration); the data 
are normalized to the controls. Scale bar in a, b, 25 µm. (For the quantification: EAE, n=6 mice; 
Healthy, n=3 mice). 
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To confirm the outside-inside spread of OL pathology, I next reconstructed the morphology 
of single OLs. The PLP-GFPm strain is a highly efficient reporter in which nearly 100% of 
the OLs and their processes are positive for GFP. Consequently, the visualization of single 
cells is virtually impossible. Thus, for this purpose I have injected Rabies Virus SAD ΔG 
mCherry in the lumbar spinal cord. Rabies virus is normally used as a virus for neuronal 
tracing as it spreads trans-synaptically in retrograde direction (Wickersham et al., 2007a; 
Wickersham et al., 2007b; Mebatsion et al., 1996; Etessami et al., 2000). In my experiment, I 
have injected a low concentration of the virus in the dorsal white matter of PLP-GFPm x 
BiozziABH immunized mice, resulting in only few mCherry positive cells. I was then able to 
selectively choose OLs based on the co-expression of GFP and mCherry, and perform 
analysis and 3D reconstruction on these OLs (Fig. 20 a-b).  
With this strategy of labeling, it was easy to study the morphology of the OLs: the cell body 
does not seem to be altered in EAE mice compared to non-immunized controls. However, 
OLs processes appear damaged and visibly fragmented. The quantification shows that OL 
processes were fewer, as well as significantly shorter than in controls groups (Fig. 21 a-b).  
Taken together, these data suggest that in our mouse model the neuroinflammatory process 
damages myelin first, then it spreads to OLs processes and only at the later stages affects the 
somata, thus following an outside-inside gradient.  
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Figure 20 - Single cell labeling. Recostruction of a single OL infected with Rabies Virus and 
transgenically positive for GFP. (a) Healthy OL, with straight and long processes; (b) OL from a sick 
animal, with short and damaged processes. Scale bar in a, 100µm (rendering) and 20µm (inset); in b, 
100µm (rendering) and 20µm (inset). 
 
 
 
 
 
 
 
 
 
Figure 21 - Analysis of OLs processes. The OLs processes of immunized animals at On+2 are 
significantly shorter (a) and less in number (b) than those in healthy animals. (Controls, n=8 mice; 
EAE, n=8 mice) (*** P<0.001). 
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Imaging myelin loss in vivo 
  
As myelin is the first target of the inflammatory attach in the EAE model I established an in 
vivo imaging approach to study myelin damage in EAE. For this purpose the animals were 
immunized with MOG protein and imaged two days after the onset of the disease (acute 
timepoint). The lumbar spinal cord was exposed as discussed in section 1 of the Results and 
MitoTracker Red was applied to label myelin, while POPO-1 Iodide was used to visualize 
nuclei. Fig. 22 a shows the in vivo appearance of an inflammatory lesion, with YFP+ axons 
looking damaged, numerous infiltrating immune cells and ongoing myelin fragmentation. 
Analysis of the myelination  status showed that in the center of an acute EAE lesion, roughly 
80% of the axons are either fully or partially demyelinated; when we look at the border of the 
lesion, we can observe that half of the axons are still myelinated indicating that 
demyelination is ongoing (Fig. 22 b). 
 
Figure 22 - (a) In vivo image of an acute lesion in an YFP16xBiozziABH animal; axons show 
swellings and myelin appears fragmented. (b) Quantification in fixed tissue of the myelination status 
in axons of YFP16xBiozziABH two days after the disease onset. In the lesion center, where the 
infiltration density is high, the majority of the axons are demyelinated; the further you go from the 
lesion center, the more axons show an intact myelin sheath. Scale bar in a, 50 µm. 
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By continuously imaging lesion border areas over time, I observed the formation of peculiar 
myelin structures characterized by a bulb-like shape, which we named “myelinosomes”. 
These myelin outfoldings grow in size over time and can be observed in EAE animals but not 
in non-immunuzed control animals. I have quantified their presence at different timepoints of 
the disease, and I found the highest density at the acute timepoint (two days after onset) 
correlating with disease severity, while none of these structure are observed in healthy 
animals, leading to the assumption that myelinosomes formation might be a mechanism of 
myelin removal (Fig. 23). Myelinosomes were also found, though with a much lower 
frequency, at the onset of the clinical symptoms and at chronic timepoint of EAE (20 days 
after the onset of the second relapse).  
Figure 23 - In vivo time lapse and quantification. (a) In sick animals I have noticed the formation of 
myelin outfoldings that become bigger and bigger with the progression of the time. We have named 
these myelin structures “myelinosomes”. Myelinosomes can carry inside myelin debris, to which I 
refer as myelin inclusion. (b) fixed tissue quantification show that myelinosomes have the highest 
frequency at the peak of EAE disease, acute timepoint. (Healthy, n=3 mice; Acute, n=6 mice; Early 
chronic, n=3; Late chronic, n=5).  Scale bar in a, 5 µm. 
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Correlated light and electron microscopy of myelinosomes 
 
In 2011 Bishop and colleagues (Bishop et al., 2011) described near-infrared branding (NIRB) 
as a method to successfully correlate light microscopy and electron microscopy (EM). I have 
used the same technique to confirm our in vivo findings and correlate them with an 
ultrastructural analysis.  
Briefly, I used an infra-red laser to create “branding” marks in the proximity of myelin 
structures of interest. These marks become autofluorescent and visible through photo-
oxidation; thus, the targeted area could be easily identified in serial ultrathin sections (for a 
detailed protocol see Bishop et al., 2011). Fig. 24 a shows a myelinosome detected with light 
microscopy; branding lines are visible and surround the structure of interest. The sample was 
then processed for EM and ultrathin sections were serially cut. The 3D reconstruction is 
shown in Fig. 24 b.  
This ultrastructural study confirmed that myelinosomes are formed by myelin leaflets and 
that the debris inside the myelinosome, often seen during in vivo imaging sessions or fixed 
tissue quantification, are themselves part of the myelin sheath (Fig. 24 c and d).  
This study at the electron microscope was possible thanks to the help of Prof. Dr. Bishop at 
the Indiana University School of Medicine, IN (USA). Prof. Dr. Bishop performed the tissue 
processing and the ultrathin serial cut of the sample, while I took care of scanning it with the 
electron microscope and actively helped with the 3D reconstruction.  
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Figure 24 - Correlated light and electron microscopy. (a) Example of a myelinosome detected in a 
spinal cord lesion of a YFP16xBiozziABH sick animal; myelin is stained with MitoTracker Red and 
shown here in magenta. NIRB marks are boxing the myelinosome in order to allow to find the 
targeted area while performing the serial cut for EM. (b) The sample was first serially cut and then 
reconstructed to obtain a 3D image of the structure. (c) EM image showing the targeted myelinosome 
and its inclusion. Myelin is colored in magenta. (d) High magnification of the inclusion confirms that 
it is made of myelin.  Scale bar a, 20 µm (overview) and 10 µm (inset); d, 200 nm. 
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Insight into the mechanism of myelinosome formation 
Ultrastructural analysis 
The ultrastructural analysis of myelinosomes helped us to better characterize the morphology 
and composition of these myelin outfoldings. In fact, sometimes the myelinosome encompass 
the entire myelin sheath, as shown in Fig. 24. Some other times, it appears to be formed only 
by one or few myelin leaflets (Fig. 25 insets).  
Figure 25 - Ultrastructural analysis. (a) On the left, 3D reconstruction of two myelinosomes on the 
same axon found at the acute peak of EAE. On the right, EM images of higher magnification of the 
myelinosomes. From the upper example we can note that sometimes myelinosomes are composed by 
single (or few) myelin sheath. Interestingly, the structures are surrounded by two big cells, likely 
monocyte-derived macrophages, which are wrapping and engulfing the myelinosomes. Myelin is 
colored in magenta, while the immune cells in cyan and blue. Scale bar in a, 1 µm (cube) and 1 µm 
(insets). 
 
Interestingly, myelinosomes usually appear in direct contact with other cells. As already 
discussed previously, lesions in the EAE model are generally characterized by a high density 
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of immune cells, mainly infiltrating macrophages, granulocytes and leukocytes but also 
activated resident microglia. Fig. 25 shows the 3D reconstruction of two myelinosomes 
forming on the same axon. It is interesting to see that those two myelin outfoldings are still 
attached to the axon by a small myelin bend. However, the cells processes wrapping the two 
structures are highly suggestive of an active process of myelinosome engulfment and 
phagocytosis. To characterize the cell type that contacts the myelinosomes, I used CCR2-
RFPxBiozziABH animals, in which monocytes-derived macrophages express red fluorescent 
protein. In all cases studied (n=3 mice), the myelinosome was surrounded by MDMs, which 
suggests that those cells that I observed at the ultrastructural level are most likely invading 
phagocytes. 
 
Antibodies transfer experiment 
In our working hypothesis phagocytic cells interact with myelin in order to form a 
myelinosome, pull it off and consequently engulf it, therefore directly contributing to the 
demyelination process. Considering the high amount of autoantibodies that are likely present 
in an EAE lesion, we hypothesized that the formation of myelinosomes is initiated by an 
antibody-mediated process. While autoantibodies can recognize specific myelin proteins, 
macrophages express the Fc receptors which can bind the Fc fragment of an antibody, thus 
opsonizing the marked cellular structures. To determine whether our assumption is correct, I 
have used an antibody transfer approach. The experiment involves the injection of specific 
antibodies (in this case I injected the anti-MOG monoclonal antibody 8.18C-5, kindly 
provided by Dr. Krishnamoorthy) at given time points during the course of EAE (Urich et al., 
2006; Pöllinger et al., 2006). Importantly, this experiment was carried out in the Bl6 strain, 
in which anti-CNS inflammation is dominated by CD4+ T cells, while the involvement of 
antibodies and B cells is very limited (Lyons et al., 1999). In order to visualize neurons and 
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their axons, this EAE model was induced in Thy1-Y16/Bl6 mice. Following immunization 
with MOG35-55 peptide, the anti-MOG monoclonal antibody 8.18C-5 was injected i.p. for 3 
consecutive days starting at the day of the onset, while the controls were treated with an IgG 
isotype control. The animals were sacrificed at onset+3. Prof. Dr. Merkler at the University of 
Geneva and his group helped me with the classical histopathological stainings, which I then 
analyzed for demyelinated area, inflammatory index and axonal density, as discussed before.  
The results show that the animals treated with anti-MOG antibodies show significantly more 
demyelination compared to the EAE controls which received an isotype control antibody, in 
line with previous publications showing that anti-MOG mAbs administration significantly 
exacerbates EAE and myelin pathology (Piddlesden et al., 1993; Linington et al., 1988; 
Litzenburger et al., 1998; Morris-Downes et al., 2002) (Fig. 26 a). As expected from this 
EAE model, the axon pathology is very severe, with less than 50% of axons surviving the 
insult; however there was no difference between the anti-MOG treated animals and the 
controls in terms of axon damage (Fig. 26 b).  
Figure 26 - Histopathological analysis and myelinosomes quantification. As shown in a) animals 
treated with 8.18C5 Abs have a significantly higher demyelination, in line with previous studies. The 
axonal pathology (b) is severe and no difference is seen among the groups. c) The quantifycation of 
the number of myelinosomes shows that the density is higher in 8.18C5 treated samples. (Ctrl=8 
mice; 8.18C5 treatment=8 mice). Scale bar a, 50 µm. (* P<0.005). 
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Particularly interesting was the quantification of the density of myelinosomes: anti-MOG 
treatment led to a more pronounced demyelination and also doubled the density of 
myelinosomes (2.3±0.2 myelinosomes/mm compared to 1.2±0.3 myelinosomes/mm) 
compared to isotype control administration (Fig. 26 c).  
The inflammatory index shows that the 8.18C5 treated mice have an higher number of 
inflammatory loci; to determine whether there is a difference in the inflammatory cells that 
compose the lesions, I further quantified the number of T cells (CD3+) and macrophages 
(Mac3+) within a given area (stainings were performed by Prof. Dr. Merkler): no difference 
in the composition of inflammatory cells could be observed among the different experimental 
groups (Fig. 27). 
 
Figure 27 - Inflammatory cell composition. Infammatory cells that characterize a lesion are mainly T 
lymphocytes and macrophages/microglia. To assess whether there is a difference in the cell types that 
form the lesions, I have quantified the density of CD3+ and Mac3+ cells.  As shown in a) and b), 
there is no significant difference between controls and treated animals, although a decrease is 
observed in the number of CD3+ cells. Scale bar a and b, 50 µm. 
 
All together, these data suggest that autoantibodies may play a major role in the formation of 
myelinosomes and consequently on demyelination.  
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B cell depletion approach 
To further investigate and confirm the role of antibodies in myelinosome formation, I have 
tried to manipulate the number of circulating antibodies: if the antibody titer is lowered and 
our hypothesis is correct, then I should observe a less severe demyelination and lower 
number of myelinosomes.  
Rituximab, one of the new agents currently under investigation as potential therapy for MS, 
targets CD20 protein on B cells thus inducing cell death. I have used the same approach and 
injected anti-CD20 antibody as previously described (Weber et al., 2010; Simmons et al., 
2013). In the latter studies, treatment with anti-CD20 antibodies ameliorated EAE clinical 
symptoms in C57/Bl6 mice. While I successfully reproduced these results in a test round of 
experiments using MOG-immunized C57/Bl6 animals, I failed to obtain a satisfying B cell 
depletion in BiozziABH/Bl6 mice. Probably due to the genetic background of this mixed 
mouse strain, B cell depletion in these mice is not fully effective and the antibody titer is only 
partially reduced. I have repeated the experiment several times to confirm this result which, 
unfortunately precluded further analysis of the B cell depletion approach in the Biozzi ABH 
model.  
  
Complement depletion experiment 
 
Antibodies can mediate their action through the activation of the complement cascade, with 
C1q recognizing the Fc fragment of Abs and initiating the classical pathway. To test whether 
this mechanism of action is responsible for the formation of myelinosomes and consequent 
demyelination, I injected Cobra Venom Factor (CVF). A single i.p. injection of CVF is 
enough to decomplement experimental animals (Vogel and Fritzinger, 2010; Hundgeburth et 
al., 2013; Ramaglia et al., 2012).  Thy1-Y16/Bl6 mice were immunized with MOG35-55, and 
injected with CVF to deplete the complement followed by 3 consecutive injections with 
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8.18C-5 anti-MOG to induce an Abs response, starting at the onset of clinical symptoms. 
Two control groups were added, respectively injected either only with 8.18C-5 anti-MOG or 
with Isotype control. Both groups injected with 8.18C-5 show a stronger disease and higher 
scores (Fig. 28 a). Interestingly, complement depleted animals have a low density of 
myelinosomes comparable to the control group (CVF-treated animals 1.17±0.2 
myelinosomes/mm, Isotype control 1.08±0.3 myelinosome/mm), thus indicating a crucial 
role of the complement system in demyelination (Fig. 28 b).  
 
Figure 28 – Complement depletion experiment. a) After immunization, animals injected with CVF 
and consequent 8.18C-5 anti-MOG show severe EAE symptoms compared to the isotype control 
group. b) The density of myelinosomes in animals depleted of the complement system is instead quite 
low, thus indicating that the complement plays a crucial role in the formation of myelinosome and 
consequent demyelination. (Ctrl=8 mice; 8.8C5=7 mice; CVF+8.8C5=8 mice). (* P<0.05).   
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Relevance for the human pathology  
 
Sequence of demyelination in MS 
The results from the animal models should in the end help to better understand how the 
process of demyelination occurs in the human pathology. I therefore received biopsies from 
patients affected by MS (kindly provided by Prof. Dr. Wolfrag Brück, Univ. Göttingen, and 
stained by Prof. Dr. Merkler, Univ. Geneve) and characterized their pathology. All the 
biopsies show active demyelinating lesions, characterized by ongoing myelin loss, high 
number of infiltrating cells and presence of myelin debris in the cytoplasm of macrophages.  
For my work, I have quantified the number of OLs within the lesion area, at the lesion border 
and in the NAWM. Interestingly, while myelin is mostly lost in the lesion center and 
preserved in NAWM regions, the OLs number is comparable between the different areas 
(Fig. 29). These results suggest that myelin is the first target of the immune attack also in 
human MS lesions. 
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Figure 29 - Pathology of MS lesions. a) Overview of an active demyelinating MS biopsy stained for 
OLs marker NOGO-A (green), for myelin marker MBP (magenta) and with the nuclear dye DAPI 
(cyan). There can be distinguished three different areas, defined as the lesion center, the lesion rim 
and the NAWM. b) Higher magnification of OLs, myelin and nuclei, in the lesion center, rim and 
NAWM. c) Quantification of the total myelin length shows a significant decrease in the lesion areas 
compared to the NAWM. d) The density of activated microglia was quantified counting Iba1+ cells; 
as expected, the graph shows a higher density whitin the lesion. e) The total number of cells indicates 
a slight higher density in the center and rim of the lesion, probably due to the high number of 
infiltrating cells. f) Interestingly, OLs density appears to be rather consistent within the different 
areas, suggesting that OLs damage happens secondarly to myelin loss. (Biopsies n=6) (** P<0.01; * 
P<0.05). Scale bar in a, 200 µm, b, 20 µm.  
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Parallelism with the murine myelinosomes 
Interestingly, high resolution confocal analysis of the myelin structure in MS biopsies, 
revealed the presence of structures that are very similar to the myelinosomes observed in the 
EAE model. I could detect bulb-like myelin outfoldings in different areas of the biopsies: the 
highest density was found in the center of the lesion, while a smaller number of 
myelinosomes was also noted in the normal appearing white matter (NAWM). Although 
these areas are called “normal-appearing”, they can potentially show different preclinical 
pathological changes (Allen et al., 2001). Importantly, analysis of myelin in control tissue 
from patients not affected by any demyelinating disease, failed to reveal presence of 
myelinosomes, thus indicating that their presence is restricted to pathological inflammatory 
conditions in which myelin represents one of the main immune targets (Fig. 30).  
Figure 30 - MS myelinosomes.  Density of myelinosomes was quantified in control biopsies, NAWM 
and lesion center. The results show a high frequency in the lesion, while the control myelin looks fully 
healthy. (Biopsies, MS n=4, control n=3). Scale bar 10 µm. 
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CHAPTER V – Discussion 
 
1. Key findings 
 
 
 Part I: In vivo imaging as a tool to study demyelination and neuroinflammation 
Important recent advances in the field of neuroscience come from the use of in vivo 
microscopy techniques combined with novel transgenic strategies. In the past years the 
combined use of these new tools allowed the study of healthy CNS as well as neurological 
disorders, allowing for example to investigate axon degeneration and regeneration in the 
injured spinal cord (Kerschensteiner et al., 2005; Ertürk et al., 2007; Debarbieux et al., 
2009), or cellular interactions and axonal pathology during neuroinflammation 
(Bartholomäus et al., 2009; Nikic et al., 2011; Siffrin et al., 2010; Breckwoldt et al., 2014; 
Sorbara et al., 2014).  
The first project presented in this thesis, helped to further expand the range of tools available 
for in vivo microscopy. To achieve this I have determined the ideal concentration and the best 
in vivo imaging settings for a set of commercially available vital dyes that have previously 
been primarily used in in vitro studies. I could show that the application of vital dyes 
provides a comparably easy and efficient way to label specific cellular and subcellular 
compartments, as well as to assess the release of toxic mediators in the living nervous system 
(Romanelli et al., 2013).  
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 Part II: Pathogenesis of demyelination in EAE and MS 
The aim of this part of my thesis was to better understand the process of demyelination in 
EAE and MS. In fact, although demyelination represents one of the classical hallmarks of this 
disease, the mechanisms mediating it are not clear. The experiments presented in this thesis 
led to the following conclusions: 
 In the EAE model oligodendrocyte damage follows an outside-inside gradient: 
myelin is the first target of the immune attack; secondly, OL processes are lost 
and lastly, the OL soma is damaged. 
 Continuos imaging over several hours in an EAE lesion area showed that 
myelin is removed by formation of myelin bulb-like structures that we named 
“myelinosomes”. These myelin outfoldings are not observed in control 
animals, but are found in the EAE model where they appear with particularly 
high frequency at the peak of disease (2 days after onset). 
 EM studies helped to further characterize the morphology of myelinosomes: 
they can encompass the entire myelin sheath, or they can be formed by single 
or few myelin leaflets. 
 EM analysis also showed that myelinosomes are closely contacted by cells, 
which I further characterized to be primarily monocyte-derived macrophages. 
Those cells engulf and phagocyte the myelinosome, leaving a patch of axon 
myelin-free. 
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 Antibodies play a crucial role in the formation of myelinosomes, likely 
through complement binding and interaction with the complement receptor on 
the phagocytic cell.  
 In human samples, the mechanism of demyelination shares some similarities 
with our animal model: while myelin is lost in the center of the lesion as well 
as drastically reduced in perilesion areas, OLs somata are consinstently 
preserved in both regions and in NAWM. Furthermore myelinosome-like 
structures were also found in MS samples, suggesting that the mechanisms 
underlying demyelination in the human disease might be similar to those 
described in the mouse model. 
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2. Vital dyes: a new tool for In vivo imaging studies  
 
In my first project I described a new approach to efficiently label different cell types (such as 
macrophages/microglia or oligodendrocytes), subcellular compartments (such as myelin) and 
organelles (such as mitochondria), or to detect the release of toxic mediators (such as reactive 
oxygen species), by the local application of vital dyes previously described in in vitro studies. 
Vital dyes can thus be easily used to complement genetic labeling approaches. While 
numerous reporter mouse lines suitable for imaging of immune cells, neurons (Singbartl et 
al., 2001; Jung et al., 2000; Feng et al., 2010), or myelin producing cells (Karram et al., 
2008; Hirrlinger et al., 2005; Mallon et al., 2002; Viganò et al., 2013) are now available, the 
creation of new transgenic lines especially if different labels are to be combined, is often 
time-consuming and expensive. Thus the combined application of one or more vital dyes to a 
specific reporter mouse line could help to address several questions in a single in vivo 
experiment. For example, in my second project foused on the study of demyelination in EAE, 
I have used a specific vital dye to label myelin in conjunction with a well established 
transgenic mouse line that provides a spectrally distinct labeling of neurons and their 
connections. 
Considering the increasing interest in the use of in vivo microscopy to study CNS disease 
models (Siffrin et al., 2010; Mues et al., 2013; Nikic et al., 2011; Sorbara et al., 2014; 
Misgeld and Kerschensteiner, 2006; Sorbara et al., 2012), a fast and reliable labeling 
technique, such as the hereby described application of vital dyes, represents a useful strategy 
to further enhance and expand the available toolset for such experiments (Romanelli et al., 
2013). 
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3. Oligodendrocyte damage and demyelination in mice 
 
Since its first description in 1933 (Rivers et al., 1933), EAE has been the most commonly 
used model to study MS pathogenesis. Among others it helped to understand, which cell 
types are involved in the initiation of a neuroinflammatory lesion. However, some open 
questions remain to be addressed; in particular it is still debated which mechanisms drive OLs 
impairment and demyelination in neuroinflammatory lesions. Here I suggest that the 
detriment starts at the myelin level and consequently spreads towards the OLs cell body in an 
“outside-to-inside” gradient (Fig. 31). Furthermore, I provide in vivo evidence for a novel 
mechanism of myelin damage, and suggeste that myelin removal might be a multistep 
process mediated by the binding of autoantibodies to the myelin that activate mononuclear 
phagocytes via complement. 
  
Demyelination as an outside-inside process 
The sequence of events that characterizes oligodendrocyte damage remains unclear and 
different hypothesis have been proposed regarding the site where damage to OLs is initated: 
myelin and its proteins (MBP, MOG, MAG, PLP), OLs processes that mediate the 
communication between OLs soma and myelin, or the cell body itself. To answer this 
question, I have used mice on a BiozziABH genetic background in which, contrarly to the 
widely used C57Bl6 animals, extensive primary demyelination occurs over the course of 
EAE (Biozzi et al., 1972; Baker et al., 1990; Amor et al., 2005). Two days after the onset of 
the clinical EAE symptoms, the results show extensive myelin damage not only in the lesion 
center but also at the lesion border. On the contrary OLs loss, is only observed in the lesion 
center (Fig. 19). It is known that with disease progression there is a significant loss of all 
three OLs compartments (myelin, OLs processes and OLs cell bodies). However our findings 
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imply that 1) the damage to myelin is not secondary to OLs death but it rather is the primary 
target; 2) myelin loss correlates with the number of infiltrating cells, reinforcing the already 
known notion that immune cells act as mediators of demyelination.   
Figure 31 – Oligodendrocyte damage follows an outside-to-inside gradient starting with myelin loss, 
spreading towards oligodendrocytes processes and finally to oligodendrocyte cell bodies.  
 
The finding that myelin represents the first target of the immune attack and not OLs cell 
bodies as suggested previously (Barnett and Prineas, 2004), is in line with the studies 
describing that in the majority of MS cases demyelination appears to follow an “outside-to-
inside” gradient (Lucchinetti et al., 2000; Lassman et al., 2001). It is likely that myelin itself 
can be an target for the immune attack; its proteins are well-known autoantigens in 
experimental models and autoantibodies against MOG, PLP and MBP are described in 
subsets of MS patients (Pröbstel et al., 2011; Derfuss and Meinl, 2012; Quintana et al., 
2012). Work in animal models would also suggest that autoreactive myelin-specific T 
lymphocytes play an important role in the pathogenesis of MS (Babbe et al., 2000; Skulina et 
al., 2004).       
The reconstruction of single OLs reconstruction in EAE and healthy animals, achieved 
through the injection with Rabies Virus SADΔG-mCherry (Wickersham et al., 2007a; 
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Wickersham et al., 2007b; Mebatsion et al., 1996; Etessami et al., 2000; Wickersham et al., 
2010) in a transgenic PLP-GFP mouse line (Mallon et al., 2002), confirmed the centripetal 
direction of OLs damage (Fig. 20). Distal and proximal oligodendrocyte processes in EAE 
lesions appeared fragmented, and were fewer in number and shorter than those in the controls 
(Fig. 21).  
All together our data support the hypothesis that OLs death is not the primary event in the 
process of demyelination. Although primary OLs damage is commonly seen in different 
pathologies, such as virus-induced inflammatory demyelination (Johnson and Ludwin, 1981; 
Rodriguez et al., 1995) and white matter ischemia (Aboul-Einen et al., 2003), and in the past 
years many efforts were made to find drugs aimed to enhance OLs survival and increase their 
differentiation (i.e. Benztropine, Deshmukh et al., 2013), our data encourage instead the 
development of new therapeutic strategies focused on preserving myelin from the immune 
attack. 
 
Time lapse in vivo imaging reveals myelin abnormalities 
In order to learn how demyelination occurs in EAE, I have used an in vivo imaging approach 
that has previously helped us to to investigate axons dynamics and mitochondria transport in 
a similar disease model (Nikic et al., 2011; Sorbara et al., 2014).  To directly visualize the 
demyelination process I applied the vital dye MitoTracker Red to label myelin (Romanelli et 
al., 2013) in a Thy1-XFP transgenic line (Feng et al., 2010) that revealed the axonal 
counterparts. As described previously (Nikic et al., 2011; Romanelli et al., 2013; Sorbara et 
al., 2014) when looking at the spinal cord of an immunized animal, axons show swellings and 
often appear fragmented, while intact myelin sheaths in these areas are partially lost and 
replaced by myelin debris. The local application of a nuclear dye allowed the visualization of 
infiltrating cells in vivo (Romanelli et al., 2013), which made the identification of EAE 
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lesions easier. When I then imaged the same area with higher resolution over time, myelin 
appears damaged and bulb-like structures are visible within the lesion. Such structures, which 
we named myelinosomes, are frequently found 2 days after the disease onset when 
demyelination is particularly severe. Their morphology is similar to myelin outfoldings which 
appear to increase over the time (Fig. 23), and likely represent the initial stage of 
demyelination.  Although the data reported in this thesis represent the first report of an in vivo 
time course of myelin outfolding formation in EAE, the findings that such myelin 
abnormalities can be in dysmyelinating diseases is not fully new. In fact, biopsies from 
patients affected by Charcot-Marie-Tooth Type 4H, a neurological disorders that damages 
Schwann cells (responsible for the myelination of axons in the peripheral nervous system) 
and reduces nerve conduction velocity, have revealed profound myelin abnormalities, 
characterized by myelin infoldings and outfoldings (De Sandre-Giovannoli et al., 2005; 
Stendel et al., 2007; Fabrizi et al., 2009). Mice lacking Fabrin/Fgd4, a member of the family 
of Cdc42-specific guanine nucleotide exchange factors (Nakanishi and Takai, 2008), show 
dysmyelination during early peripheral nerve development with the formation of aberrant 
myelin structures (Horn et al., 2012). Same myelin abnormalities also appear when Mtmr2, 
the myotubularin-related 2 gene, is inactivated in Schwann cells (Bolino et al., 2012; Pereira 
et al., 2012). While myelin outfoldings have usually been linked to pathological disorders, a 
recent paper described the presence of redundant myelin also at early stages during 
development in the optic nerve; this accumulation of excess membrane spreads out along the 
myelin sheath during development and gradually disappears in adult life (Snaidero et al., 
2014a). Comparable structures were also previously found in the proximity of nodes of 
Ranvier in EAE by ultrastructural examination (Yamasaki et al., 2014). 
In our animal model, the formation of myelinosomes correlates with disease progression, 
with only few myelinosomes observed at the onset of EAE and an increased frequency 2 days 
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after disease onset when demyelination reaches its peak. Myelinosomes are also seen with a 
high density two days after a disease relapse, while they decrease at a chronic time point 
when the majority of the axons have already been demyelinated. In the healthy adult spinal 
cord myelinosomes are never seen, thus reinforcing that their presence is restricted to the 
pathological condition. 
An interesting point to mention is the relationship between axonal and myelin degeneration. 
Despite the widely held view that MS is a primary demyelinating disease in which axon 
damage happens secondarly to myelin loss, studies have suggested that in some 
remyelinating and inactive MS lesions (Bitsch et al., 2000; Kornek et al., 2000; Kuhlman et 
al., 2002) as well as in EAE (Nikic et al., 2011), axons can be damaged independently from 
their myelinating/demyelinating status. My results support this notion, as I find 
myelinosomes surrounding normal appearing axons as well as axons undergoing 
degeneration. This further confirms that axonal pathology and demyelination might occur 
independently from each other and might indeed be triggered by different mechanisms. These 
results must be kept in mind when developing new therapeutic strategies, because a drug 
which is effective for the prevention of myelin destruction, might not automatically protect 
axons from degeneration. 
 
Utrastructural analysis of myelinosomes 
The in vivo visualization of myelin is based on the application of the vital dye MitoTracker 
Red (Romanelli et al., 2013). Being a highly lipophilic dye, it can easily penetrate 
membranes, therefore sometimes its labeling is not only restricted to myelin. Hence, an 
argument that could be raised is that myelinosomes might be artefacts of the labelling itself.  
Considering that I did not detect myelinosomes in control animals even after long imaging 
sessions and even though we were confident that myelinosomes are not artefacts of the 
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labelling, to fully exclude this possibility I performed electron microscopic analysis of 
myelinosomes. This helped not only to clarify their composition but also to better 
characterize their morphology and interaction with adiacent cells.  
Part of this study was conducted based on a novel technique previously described to correlate 
light and electron microscopy (“near-infrared branding (NIRB)”) (Bishop et al., 2011), that 
relies on the use of fiducial “branding” marks which photo-oxidize after exposure to 
diaminobenzidine (DAB), thus allowing to be recognized at the electron microscopic level 
(Bishop et al., 2011). With this method, I excluded the possibility of myelinosomes being 
artefacts and confirmed that they are indeed outfoldings of the myelin sheath which 
sometimes carry inside fragments of myelin debris (inclusions) (Fig. 23 - 24).  
Further EM studies also shed light on the composition of myelinosomes, showing that they 
can encompass the entire myelin sheath or they can be made up of only few myelin leaflets 
(Fig. 25). This might be explained by the original thickness of the myelin sheath. It is indeed 
known that there is a correlation between myelin and axon diameter (Friede and Samorajski, 
1967; Elder et al., 2001): thinner axons have a thinner myelin sheath, while big caliber axons 
require a thicker myelin. Thus, on the one hand when the axon is thin, myelinosomes might 
be formed by the whole myelin sheath; on the other hand, when the axon is thick, the removal 
of myelin might require more steps and the formation of several myelinosomes each 
composed by few myelin layers.  However, myelin is a very tightly packed structure and in 
order for the single-leaflets myelinosomes to form, the interactions among myelin stacks 
must be loosened. It was recently proposed that MBP, one of the major components of 
compact myelin (Privat et al., 1979), thanks to its capacity to go through phase transition is 
responsible for myelin assembly and aggregation (Aggarwal et al., 2013). On the contrary, 
when MBP changes from a condensed to a dispersed phase, it might induce myelin 
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disassembly, leading to detachment among myelin leaftlets which in turns might favor the 
formation of single-leaflet myelinosomes.  
 
4. Involvement of the immune system  
 
As I already summarized in the Introduction (see section “Animals model of demyelination 
and inflammation”), different components of the immune system are involved in the 
formation of new lesions in EAE. However macrophages, derived either from resident 
microglia (MiDMs) or from circulating monocytes (MDMs), are the main cells that compose 
a classic neuroinflammatory lesion and their density usually correlates to EAE severity 
(Huitinga et al., 1990, 1993; Ajami et al., 2011). Here I show that they also play a crucial role 
in the initiation of demyelination. Specifically through the interaction with anti-MOG 
antibodies they contribute to the formation of myelinosomes and consequently to myelin loss. 
 
Macrophages interaction 
The electron microscopic study was helpful to show the relationship of myelinosomes with 
the surrounding cells. Here I observed that adiacent cells always reach out to contact and 
engulf myelinosomes (Fig. 25). Myelinosomes are formed predominantly 2 days after onset, 
when demyelination is known to be particularly severe and the density of infiltrating immune 
cells significantly high. Given their preferential occurence at the demyelination peak and the 
close contact with phagocytic cells, we propose that myelinosomes are a mechanism of 
myelin removal which is responsible for demyelination in the EAE model. To understand 
which cells initiate myelinosome formation, I used a transgenic mouse line that allows to 
discriminate between MiDMs and MDMs (Saederup et al., 2010; Mizutani et al., 2012). The 
finding that phagocytes contacting myelinosomes always belong to the monocytes-derived-
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macrophages family (MDMs) means that those cells are likely involved in the process of 
myelinosome formation. The result is in line with the data presented by Yamasaki and 
colleagues, suggesting that MDMs and MiDMs exert different roles in EAE pathology, with 
MDMs responsible for the initiation of demyelination starting in the proximity of the node of 
Ranvier, while MiDMs are involved in the removal of myelin debris (Yamasaki et al., 2014).  
Macrophages are known to act as mediators of axon damage and mitochondrial dysfunction 
(Smith and Lassman, 2002; Lin et al., 2006; Nikic et al., 2011) through the release of toxic 
factors, which may also be responsible for myelin destruction (Bitsch et al., 2000). However 
our data argue for a rather active and mechanic role of macrophages in myelin removal. In 
fact, due to the peculiar morphology of myelinosomes and their close vicinity to phagocytic 
cells, we can speculate that a tight interaction between myelin and the cell itself does exist. 
This bond helps the macrophage to physically pull off myelinosomes, engulf them and leave 
a patch of axon myelin-free. Given the presence of potential phagocytic signals, such as 
immunoglobulins and opsonins (Nauta et al., 2004) or eat-me signals (Hochreiter-Hufford 
and Ravichandran, 2013), which can be recognized by specific receptors on macrophages 
implicated in phagocytosis like the scavenger receptor SRA-I/II, Fc Receptor, C1q and C3b  
receptors (Winther et al., 2012; Hogarth and Piertersz, 2012; Hadas et al., 2012; Smith, 
2001; Reichert and Rotschenker, 2003), it will be important to identify the molecular 
mechanism initiating the formation of myelinosomes, and eventually to selectively 
manipulate it in order to prevent demyelination.   
 
Antibodies and myelinosomes formation 
Although MS is recognized as a T cell-mediated autoimmune disease, the presence of 
oligoclonal Igs and plasma cells in the CSF is widely used to diagnose the disease (Egg et al., 
2001; Warren et al., 1994), suggesting that antibodies (Abs) might play a role in the 
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pathology of MS. I have hypothesized that Abs might as well be involved in demyelination 
and myelinosome formation identifying surface myelin proteins as antigens and consequently 
interacting with the surrounding macrophages/phagocytes.  
I have injected anti-MOG mAb in Y16/Bl6 mice after immunization with MOG35-55, a model 
in which normally the role of B cells and Abs is very limited and the disease is predominantly 
driven by T cells. I found that the treatment with anti-MOG mAbs induces exacerbation of 
demyelination, in accordance with previous reports (Piddlesden et al., 1993; Linington et al., 
1988; Litzenburger et al., 1998; Morris-Downes et al., 2002). Of particular interest was the 
finding that the density of myelinosomes is significantly increased after anti-MOG Abs 
injection (Fig. 26). From former studies, it is known that in the EAE model the role of Abs 
and their producing cells is still controversial, with some evidence suggesting a pro-
inflammatory role with amelioration of the clinical symptoms after B-cells depletion (Lyons 
et al., 1999; Weber et al., 2010), and others describing a rather protective role (Weber et al., 
2010; Simmons et al., 2013). My findings point in the direction of a destructive action of anti-
myelin Abs and suggest that myelinosome formation and demyelination are antibody-
mediated processes. Specifically MOG, one of the few surface proteins that is exposed on the 
myelin sheath, seems to be the target of the autoantibodies attack. Indeed, anti-MOG 
autoantibodies have also been described in the serum of a subgroup of (pediatric) MS patients 
(Pröbstel et al., 2011). 
A potential confounder in this experiment could be that the higher density of myelinosomes 
observed after anti-MOG Abs injections might be due to a different density of macrophages 
and T cells within the lesions after Ab application. However, analysis of inflammatory 
lesions revealed no difference both in the density of T cells (CD3+) and 
macrophages/microglia (Mac3+) between the treated animals and the controls. This further 
confirms that myelinosome formation is dependent on the number of antibodies capable of 
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binding MOG proteins. If we want to spare axons from demyelination we therefore need to 
act on 1) reducing the titer of Abs that can potentially bind myelin proteins and 2) interfere 
with the mechanism of action of the Abs, thus preventing them to interact with 
macrophages/phagocytes. 
 
Myelinosome formation as an antibody-complement mediated mechanism 
In order to prevent demyelination a question that will be helpful to answer, is throughout 
which pathways and receptors Abs exert their function.  
Abs can elicit their effector function through activation of the complement system initiating 
the classical complement pathway (Botto et al., 1998; Kishore et al., 2000). By injecting with 
cobra venom factor (CVF), commonly used to decomplement experimental animals (Vogel 
and Fritzinger, 2010; Hundgeburth et al., 2013; Ramaglia et al., 2012), I studied the role of 
the complement system in regard to its interaction with antibodies in the EAE model and its 
contribution to demyelination and myelinosome formation. My data suggest that the 
complement system plays a crucial role in the formation of myelinosomes, as demonstrated 
by the low density of myelin abnormalities in the animals treated with CVF (Fig. 28). This is 
in agreement with previous studies, which lean on a major role of the complement system 
during demyelination (Urich et al., 2006; Ingram et al., 2009). A role for the complement in 
MS is known since 1971, when C3 deposits were described in the brains of MS patients 
(Lumsden, 1971); since then, numerous studies in the animal models have been aimed to 
investigate the role of the complement system in EAE pathogenesis. Recently the 
complement was the subject of a study performed in BiozziABH mice, which reported that it 
is highly activated when demyelination is ongoing during the acute, relapsing and progressive 
disease stages, while its activation is markedly diminished during remission (Ramaglia et al., 
2015).  
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The constant region of immunoglobulins can also be recognized by the FcR on macrophages 
and this bond is usually responsible for antibody-directed cell-mediated cytotoxicity (ADCC) 
(Ravetch and Clynes, 1998). Although few studies have already been conducted on the role of 
FcγRs in the pathogenesis of demyelination, which concluded that FcγRs are not involved in 
the processes leading to the myelin loss (Urich et al., 2006; Breij et al., 2005), we are 
currently performing experiments using FcγR quadruple knockout mice (deficient in both the 
activatory and inhibitory FcγRs - I, II, III and IV -). This will help to clarify whether FcγRs 
play a role in the formation of myelinosomes or not.  
The finding that complement system in involved in myelin damage opens new feasible 
therapeutic strategies to prevent myelin destruction and suggests the complement system as a 
new potential target for drug development. 
 
5. Relevance for MS 
 
Considering that the current literature does not provide a conclusive answer on the sequence 
of demyelination in MS, during my PhD work I have analyzed several active demyelinating 
MS biopsies in collaboration with the group of Doron Merkler (University of Geneva). My 
work suggests that demyelination in MS shares important similarities with the animal model, 
both in regards to the sequence that leads to myelin loss and to the mechanisms that drives it. 
 
Demyelination in MS lesions 
As previously investigated in the animal model, I first studied the sequence of myelin loss by 
measuring the density of OLs cell bodies as well as myelin length in lesion (active lesion 
center and border of the lesion) and in NAWM regions. The results show that there is a 
substantial reduction of myelin within the lesion areas compared to the NAWM regions, but 
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the density of OLs is constant among the different areas (Fig. 29). This sequence of OL 
damage is similar to the one observed in the animal model and supports the hypothesis that 
the most common demyelinating pattern in MS follows an outside-to-inside gradient. 
Lucchinetti et al. suggested that there is a profound heterogeneity in the immunopathological 
composition of the lesions, with the majority of the MS patients showing a “centripetal” 
damage, in which the autoimmune attack starts at the myelin level and later spreads towards 
the OLs bodies (pattern II), while in about 30% of MS cases the damage to oligodendroglia 
follows a “centrifugal” gradient where OLs death is the primary hallmark (pattern III) 
(Lucchinetti et al., 2000; Lassman et al., 2001) (Fig. 32). Albeit previous reports also 
describe a “variable” loss of OLs at the active lesion border with high number of OLs in the 
inactive plaque (Lucchinetti et al., 2000; Popescu et al., 2013; Storch et al., 1998), in my 
work there was no such difference.  
Although we cannot exclude that some of the OLs observed within the lesion might be 
newly-formed OLs, no sign of OLs apoptosis or degeneration are seen in the area. This 
finding is in contrast with another study describing that the formation of new MS lesions 
always starts with OLs death, microglia activation but not macrophage infiltration, and no 
structural myelin alterations (so called “pre-phagocytic lesions”) (Barnett and Prineas, 2004).  
An interesting point to note is that in my data the density of Iba1+ cells is considerably higher 
in the lesions compared to NAWM areas, suggesting that not only resident microglia is 
activated but also a substantial number of macrophages has infiltrated the area. The fact that 
the lesions described in my study show an outside-to-inside gradient with prominent 
macrophages infiltration, indicates that they belong to the previously described patterns I or II 
(Fig. 32). In light of these results, the need to develop new treatments aimed to protect 
myelin from degeneration is emerged, though drugs focused on enhancing OPCs 
differentiation or promoting remyelination (benztropine, antibody against LINGO-1, 
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monoclonal IgM antibody 22, quetiapine, etc...) (Deshmukh et al., 2013; Mi et al., 2005; 
Warrington et al., 2007; Bi et al., 2012; Kremer et al., 2014), might still be useful at later 
stages of the disease when demyelination has already reached OLs somata. 
Figure 32 – Mechanisms involved in the formation of multiple sclerosis lesions. In active lesions, four 
distinct patterns can be distinguished: demyelination is induced by macrophages and their toxic 
factors (pattern I), by antibodies against myelin proteins and complement (pattern II), by distal 
oligodendrogliopathy followed by apoptosis (pattern III), or by primary OL death followed by myelin 
damage (pattern IV). Scheme taken from Lassman et al., 2001.  
 
When I looked at the myelin sheaths in the MS biopsies at higher resolution using confocal 
microscopy, I observed myelin outfoldings that were similar to the myelinosomes described 
in the animal model lesions (Fig. 30). The density was particularly high in the lesion center 
and at the rim of the lesion, where demyelination is ongoing. Myelinosomes are also 
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detectable, although with a much lower frequency, in NAWM regions. This is not fully 
unexpected; in fact, even though they are supposed to be normal-looking areas, often NAWM 
appears mildly compromised in MS, showing astrogliosis, microglial activation, reduced 
myelin density and axonal loss (Matthews et al., 1999; Allen et al., 1979; Allen et al., 2001). 
Contrarily, when white matter areas from control patients not affected by demyelinating 
neurological diseases were analyzed, no signs of myelinosomes were found. This is 
consistent with the notion that in MS, the presence of myelin outfoldings is common and 
represents an early stage of demyelination. It is therefore crucial to study myelinosomes and 
the mechanisms that lead to their development, in order to interfere with the process and 
prevent demyelination.  
In my experiments in the animal model I have studied the role of antibodies directed against 
MOG and found that they mediate myelinosome formation and consequent demyelination. 
Considering that my findings from the human samples share similarities with EAE in terms 
of the sequence of events leading to myelin destruction and morphology of myelin 
abnormalities, one could assume that similar molecular mechanisms may also be responsible 
for demyelination in MS. Antibodies against myelin proteins, particularly MOG, are found in 
the serum of MS patients and have been described to be implicated in demyelination in a 
subgroup of MS lesions (Storch et al., 1998; Lucchinetti et al., 2000; Reindl et al., 2006). 
Knowing which antibodies are involved in a specific disease is important not only to develop 
new therapeutic agents, but it can also be useful to diagnose and classify disease subtypes. In 
fact, the humoral response is critically involved in several inflammatory demyelinating CNS 
diseases, e.g. neuromyelitis optica (NMO) in which antibodies against aquaporin-4 are a 
characteristic and likely pathogenic component of the disease (Lennon et al., 2005). Although 
MOG is the best-characterized autoantigen, it cannot be excluded that antibodies in MS 
patients may also recognize other non-myelin proteins (such as KIR4.1, or antibodies to 
 
Discussion    -    112 
 
paranodal proteins) (Srivastava et al., 2012; Meinl et al., 2011), therefore leading to 
secondary demyelination.  
Patients affected by NMO benefit from B cells/antibody-targeted drugs which raises hopes 
that similar targeted treatment might be valuable also for the therapy of MS. At the moment, 
few similar approaches are used in the treatment of MS. Removal of pathogenic antibodies by 
plasma exchange has been proved efficacious in a subgroup of MS patients showing pattern 
II lesions during relapses (Keegan et al., 2005), while new drugs aimed to deplete B cells are 
now under consideration for the treatment of MS (i.e. Rituximab, Ocrelizumba, etc..) 
(Krumbholz et al., 2012). In addition to the already available agents, I hope that the results 
presented in this thesis will help to design more effective therapeutic strategies to protect 
myelin from immune attack e.g. by limiting the interaction between myelinosomes and 
phagocyte.
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